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Abstract
Antibody engineering and advances in microbial expression systems have
enabled production of small, active antibody fragments. However, the functional
expression yields of these recombinant antibodies vary widely. The results
described in this thesis elucidate factors influencing the expression of stable and
active antibody fragments in bacteria. The model antibody used throughout this
study was a mouse monoclonal antibody binding to 2-phenyloxazolone (Ox). It
was shown that the first constant domain of the heavy chain (CH1) has a
remarkable effect on secretion of functional and stable Fab fragments.
Comparison of the production of the Ox IgG1 and Ox IgG3 subclass Fab
fragments in bacteria demonstrated the superiority of the Ox IgG1 Fab compared
to the Ox IgG3 Fab. In addition to its effect on secretion, the CH1 domain
contributes to the thermal stability of the antibody fragments. To study the effect
of a linker peptide on both proteolytic stability and binding activity of single-
chain antibodies, six different Ox scFv derivatives and an Ox Fv fragment with
no joining peptide between the variable domains were constructed. It was shown
that joining of the variable domains with a linker peptide improved hapten
binding properties compared to the Ox Fv fragment, but may expose the
fragment to proteolytic degradation. Truncation of the linker peptide to less than
12 amino acids induced formation of dimers or multimers. The binding affinities
determined for the monomeric Ox scFv and Ox IgG1 Fab fragments using the
BIAcore biosensor and fluorescence quenching methods were close to each
other and comparable to that of the parental monoclonal antibody.
In addition to studies with soluble antibody fragments, this work was extended
to cover characterization of antibody fragments displayed on liposomes and on
the surface of baculovirus. Immunoliposomes have potential applications both in
therapy and in immunodiagnostics. In this work liposomes displaying antibodies
were generated by incorporation of purified lipid-tagged Ox scFvs expressed in
6E. coli into phospholipid liposomes. It was demonstrated that the
biosynthetically lipid-tagged Ox scFv molecules can be immobilized in a
functional, stable and oriented manner onto liposomal membranes, resulting in
immunoliposomes showing specific hapten binding. BIAcore analysis of the
immunoliposomes revealed very slow dissociation from the Ox surface, which is
in good agreement with the predicted multivalent nature of the
immunoliposomes. The baculoviral display approach holds a promise as a
candidate for a eukaryotic display system. In this work single-chain antibodies
were used as a model to investigate functional expression of foreign proteins on
the surface of baculovirus. Viral vectors displaying cell targeting moieties such
as single-chain antibodies have aroused interest as gene transfer vehicles. Two
Ox scFv derivatives and a human scFv specific for carcinoembryonic antigen
(CEA) were fused to the major envelope protein (gp64) of the Autographa
californica nuclear polyhedrosis virus (AcNPV). It was shown that the two
single-chain antibodies which contained a (GGGGS)3 linker peptide were
incorporated into the budded virus particles and expressed as functional
hapten/antigen binding fragments on the viral surface. In the case of the third
scFv containing a natural linker peptide derived from a fungal cellulase, less
efficient incorporation into the virus particles was observed.
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1. Introduction
Vertebrates have different defense mechanisms to protect themselves against
infective microorganisms and other foreign substances. Skin and mucous
membranes form physiological barriers, while B and T lymphocytes together
with antibodies provide a more specific defense mechanism to neutralize or
destroy the foreign invaders. Foreign substances that can induce an immune
response are called immunogens or antigens. Haptens are molecules which are
too small to alone act as immunogens, but which can generate an immune
response when coupled to larger macromolecules (carriers). Specific immune
responses are divided into two classes, humoral and cell-mediated, depending on
the components of the immune system which mediate the response. The humoral
response is mediated by B lymphocytes and results in secretion of specific
circulating antibodies that eliminate the antigen. In the cell-mediated response T
lymphocytes perform helper functions as well as induce and promote destruction
of cells infected by various types of viruses or intracellular bacteria.
1.1 Antibody structure
Antibodies or immunoglobulins (Igs) have a common Y-shaped core structure
consisting of two identical light (L) chains (about 25 kDa) and two identical
heavy (H) chains (50–75 kDa). One L chain is joined to each H chain and the
two H chains are joined together by disulfide bonds (Fig. 1). Antibodies are
divided into five main classes depending on the structure of the H chain. These
classes are IgA, IgD, IgE, IgG and IgM and the corresponding H chains are
designed by α, δ, ε, γ and µ, respectively. IgG antibodies can be further divided
into four subclasses: IgG1–IgG4 in humans and IgG1, IgG2a, IgG2b and IgG3
in mouse. In a complete antibody molecule, each of the H chains is joined either
to a kappa (κ) or a lambda (λ) L chain. In human serum, antibodies with κ and λ
light chains are represented in about equal numbers whereas in mice, Lκ-
containing antibodies are about ten times more frequent than Lλ-containing
antibodies. IgG and IgE antibodies circulate in the blood as monomers, whereas
IgA and IgM are found as dimers and pentamers, respectively. In addition to
dimers, IgA antibodies can exist in monomeric form. IgD is rarely secreted and
can be found as membrane-bound on the surface of B lymphocytes.
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Both the L and H chains consist of several homologous structural polypeptide
units, which fold independently forming a globular motif called an
immunoglobulin domain (or fold) (Poljak et al., 1973). In both chains the N-
terminal domains have the greatest sequence variation between different
antibody molecules and are therefore known as the variable (V) domains. These
domains form the antigen binding site of the molecule. An intact antibody
molecule is thus bivalent, containing two identical antigen binding sites (Fig. 1).
Figure 1. Structure of an IgG molecule. The heavy (H) and light (L) chain and
the variable (V) and constant (C) domains are shown. The positions of the
interchain and intrachain disulfide bonds (-S-S-) and the carbohydrate moieties
(CHO) are marked. The proteolytic cleavage sites by papain (1) and pepsin (2)
together with the resulting proteolytic fragments (Fab´)2, Fab and Fc are
indicated.
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The V regions of the H chain (VH) and the L chain (VL) contain four relatively
conserved sequence stretches called framework regions (FR1–FR4). These
structures form a scaffold for three hypervariable loops known as the
complementary determing regions (CDR1–CDR3) which contain most of the
antigen binding amino acid residues. Sequence and structure analysis of
antibody molecules have shown that five of the six hypervariable regions occur
in a limited set of main-chain conformations called canonial structures (Chothia
and Lesk, 1987). The V domains are joined to more conserved constant (C)
domains. There is one C domain in the L chain (CL), whereas their number in H
chains varies between three and four (CH1–CH4) depending on the Ig class.
Further, the H chains are characteristically glycosylated at asparagine side chains
located in most cases at the CH2 domain (Fig. 1) (Sutton and Philips, 1983).
Some antibody classes (IgM and IgA) are glycosylated at the CH1 domain
(Davies and Shulman, 1989; Young et al., 1990).
In the H chains there is a nonglobular helical sequence between the CH1 and CH2
domains specified as the hinge region. The hinge region varies in length between
different antibody classes and it confers further flexibility to the antibody
molecule. Proteolytic digestion of an IgG molecule with papain occurs at the
hinge region producing two identical monovalent antigen binding Fab fragments
(Fig. 1) each consisting of the entire L chain and the VHCH1 domains (Fd).
Pepsin digests the IgG molecule on the C-terminal site of the disulfide bonds
leaving the H chains joined. This enzyme produces thus a bivalent F(ab´)2
fragment (Fig. 1). The rest of the molecule, the Fc fragment, mediates effector
functions of the antibody. Glycosylation of the H chain contributes to antibody
stability and mediates effector functions such as complement binding and
activation (Nose and Wigzell, 1983; Muraoka and Shulman, 1989; Miletic and
Frank, 1995).
1.2 Recombinant antibodies
Antibodies can be obtained by immunizing animals with the antigen and
collecting the sera which contain a heterogeneous mixture of antibodies.
However, nowadays these polyclonal antibodies are in many cases replaced by
monoclonal antibodies (Köhler and Milstein, 1975) which have a defined
specificity, and can be produced in consistent quality. Although murine
16
antibodies have been widely used in diagnostic assays and for research purposes,
their use in human therapy is limited due to immune responses against murine
antibodies frequently observed in patients during clinical trials (Schroff et al.
1985; Shawler et al. 1985; for a review, see Colcher et al., 1998). Production of
human monoclonal antibodies by conventional hybridoma technology has
proved to be difficult due to the inefficiency of the fusion process and unstability
of the human hybridoma cell lines (James and Bell, 1987). One strategy to
circumvent this problem is to produce human antibodies in transgenic mice. In
this system endogenous murine Ig genes have been replaced with human Ig
genes so that the mice upon immunization with antigen produce human
antibodies (Brüggemann et al., 1991; Jakobovits, 1995; Brüggemann and
Taussig, 1997).
An alternative approach to decrease the immunogenicity of the murine
antibodies is to redesign or engineer the antibodies using recombinant DNA
technology. It is possible to create chimeric antibodies which contain mouse V
domains joined to human C domains (Boulianne et al., 1984; Morrison et al.,
1984). The immunogenicity can be further minimized by grafting the murine V
region CDRs in to a human V region framework, resulting in a reshaped
(humanized) antibody molecule, most of which is of human origin (Jones et al.,
1986; Morrison, 1992; Colcher et al., 1998).
Many applications involving the use of antibodies are based on their specific
binding properties, whereas their other biological functions, such as complement
activation mediated by the Fc fragment, are not necessary. The globular domain
structure of an antibody molecule is convenient for genetic engineering and
enables generation of tailor-made antibody fragments for a variety of purposes.
One advantage of the new technology is that the size of the antibody molecule
can be reduced while retaining the intact antigen binding site of the molecule.
Compared with the complete antibody molecule these minimized antibodies
have several advantages in clinical applications, including improved tissue
penetration, rapid clearance from serum and reduced immunogenicity (Colcher
et al., 1998). The small size also facilitates the expression of these functional
fragments and their fusions in bacteria (see 1.2.1) as well as allows their display
on a filamentous phage (see 1.4.1). Nowadays, human antibody fragments and
other antibodies which are difficult to obtain by hybridoma technology can be
isolated from phage-based libraries (Marks et al. 1991; Griffiths et al., 1993;
17
Nissim et al., 1994). Further, the small size of the recombinant antibody
fragments together with the efficient microbial production systems allow
production of a homogenous protein in amounts sufficient also for structural
studies (see 1.3.3).
Since the advent of modern gene technology, a wide variety of genetically
engineered minimized antibodies have been produced (reviewed in Hudson,
1998, 1999; Little et al., 2000). These include Fab fragments (Better et al.,
1988), Fv fragments in which the V domains are held together by non-covalent
forces (Skerra and Plückthun, 1988) and so called single-chain antibodies
(scFvs) in which the VH and VL domains are connected either with a short
flexible linker peptide (Bird et al., 1988; Huston et al., 1988) or with a disulfide
bond (Glockshuber et al., 1990) (Fig. 2).
Figure 2. Recombinant antibody fragments. See text for details.
The minimized antibodies can further serve as building blocks for generation of
novel recombinant proteins for different purposes. Antibody fragments of the
same specificity have been fused to generate bivalent (for reviews, see
Plückthun, 1992; Plückthun and Pack, 1997) or multivalent (Plückthun and
Pack, 1997; Hudson and Kortt, 1999) antibodies, and two antibody fragments with
different specificities have been fused to produce bispecific antibodies (Fig. 2)
(Holliger et al., 1993; Mallender and Voss, 1994; Plückthun and Pack, 1997).
Bispecific
scFv
Diabody
scFvFv
Fab
Bifunctional
antibody
Bivalent  scFv
Parental
antibody
18
Diabodies are dimeric antibody molecules that can be designed for bivalent or
bispecific interactions (Holliger et al., 1993). Diabodies or even triabodies are
formed spontaneously if an scFv has too short a linker peptide to allow pairing
of the V domains within the same polypeptide chain but instead favours pairing
between V domains in two adjacent chains (Fig. 2) (Iliades et al., 1997; Atwell
et al. 1999). Bifunctional antibodies consist of antibody fragments fused to
another functional partner, for example an enzyme (Wels et al., 1992; Carrier et
al., 1995) or a toxin (Chaudhary et al., 1989; Batra et al., 1992; Reiter and
Pastan, 1998). A fusion to a lipoprotein (Fuchs et al., 1991) or introduction of a
lipid tag (Laukkanen et al., 1993) converts a soluble antibody fragment into a
membrane-bound molecule enabling the antibody fragments to anchor on the
bacterial membranes during their production in E. coli.
1.2.1 Expression of antibodies in Escherichia coli
At present polymerase chain reaction (PCR) is commonly used to amplify the
genes encoding monoclonal antibodies with desired specificity or even to
produce the entire antibody gene repertoire of immunized or non-immunized
animals for cloning purposes. By cloning the entire Ig V region gene repertoire it
is possible to by pass hybridoma technology and the need for immunization and
experimentation with animals. Furthermore, the hybridoma cell lines are
sometimes unstable and in such cases it is advantageous to immortalize unique
antibodies by cloning the corresponding genes.
Recombinant antibodies including Fab, Fv and scFv fragments have been
produced as functional proteins in various expression hosts such as bacteria
(Better et al., 1988; Bird et al, 1988; Huston et al., 1988; Skerra and Plückthun,
1988), yeast (Horwitz et al., 1988; Edqvist et al., 1991), filamentous fungi
(Nyyssönen et al., 1993), insect cells (Bei et al., 1995), plants (Owen et al.,
1992) and mammalian cells (Dorai et al., 1994). There are some general rules
with regard to the design of vectors and expression systems used with the
different hosts and each of these hosts has advantages and disadvantages for the
production of functional antibody fragments (reviewed in Verma et al., 1998).
However, among the large arsenal of different expression strategies available for
heterologous protein production, the bacterial expression system is most often
applied for the production of recombinant antibody fragments. Recent progress
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in the understanding of both the genetics and biochemistry of Escherichia coli
makes this organism a valuable tool as an expression host (reviewed in Baneyx,
1999). An advantage of this production system is that large quantities of
homogenous protein preparation can be produced in a simple, rapid and cost-
effective manner. Very high yields up to 1–3 g/l of functional antibody have
been obtained with careful optimization of fermentation conditions (Carter et al.,
1992; Horn et al., 1996). As the antigen binding domains of an antibody
molecule are not usually glycosylated except in some rare cases (Sox and Hood,
1970; Wallic et al., 1988), the corresponding antibody fragments assume their
natural conformation in bacterial cells and can thus be obtained in their active
form.
There are several different strategies to express the recombinant antibody
fragments in E. coli (for reviews, see Plückthun and Skerra, 1988; Plückthun,
1991). One possibility is to express antibody chains directly without a signal
peptide in the cytoplasm of E. coli (Bird et al., 1988; Buchner and Rudolph,
1991). Overexpression of polypeptides expressed in the reducing environment of
bacterial cytoplasm is often accompanied by formation of insoluble aggregates
known as inclusion bodies. Therefore, to recover the correctly folded functional
form with proper rearrangement of the disulfide bonds the polypeptides must be
renaturated in vitro (Huston et al., 1995). Another strategy, which circumvents
this problem, is to use a signal peptide to direct secretion of the antibody chains
into the periplasmic space (Better et al., 1988; Plückthun and Skerra, 1988;
Skerra and Plückthun 1988). The periplasmic space lies between the inner and
outer membranes of gram-negative bacteria (Fig. 3), and it is known to contain
proteins such as chaperons and disulfide isomerases, which facilitate the correct
folding of recombinant proteins (Baneyx, 1999). Production of Fab fragments in
E. coli is usually based on the expression of a dicistronic operon unit, in which
both the L and Fd gene are under the control of the same promoter. This allows
synthesis of approximately the same amounts of both chains. The antibody
polypeptides are expressed in the cytoplasm as precursors with N-terminal signal
peptides. During translocation through the inner membrane into the oxidizing
environment of the periplasm, the signal peptides are cleaved off, the chains fold
and assemble, and both the intra- and interdomain disulfide bonds are formed
(Fig.3). This secretory pathway of E. coli is similar to eukaryotic folding and
assembly of proteins in which the polypeptide precursors are transported to the
lumen of the endoplasmic reticulum (ER). The functional and soluble antibodies
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can be easily purified from the periplasmic fraction of the bacteria (Skerra and
Plückthun, 1988; Carter et al., 1992). During prolonged induction, the outer
membrane of the bacteria often becomes leaky and the antibody fragments
accumulate into the culture medium (Better et al., 1988; Takkinen et al., 1991).
Figure 3. Expression of soluble Fab fragments in Escherichia coli. After
induction dicistronic mRNA is synthesized and translated into preproteins in the
cytoplasm of E. coli. Secretion of the H and L chains into the periplasm is
achieved by the use of signal peptides which are removed during the
translocation process across the bacterial inner membrane. The secreted
polypeptide chains fold and assemble in the oxidizing environment of the
periplasm and the formed Fab fragments leak into the culture medium.
Although periplasmic expression has been successfully used in the production of
large variety of specific antibody fragments, the efficiency of folding appears to
be dependent on the individual protein and in some cases antibodies are
observed as insoluble and non-functional material in the periplasm (Malby et al.,
1993; Smallshaw et al., 1999). Recently, thorough studies on factors improving
both phage display and periplasmic folding of scFvs have led to the
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identification of accessory proteins which decrease aggregation and facilitated
folding of the antibody fragments (Bothman and Plückthun, 1998, 2000; Ramm
and Plückthun, 2000). By optimizing those parts of an antibody fragment which
are not directly involved in antigen binding it is possible to decrease the
aggregation of the molecules and thus to improve the yield of a functional protein
(Knappik and Plückthun, 1995; Wall and Plückthun, 1999). In the scFv format
hydrophobic patches which are normally buried in a hydrophobic V/C domain
interface are exposed to the solvent, which may promote aggregation during the
folding. Substitution of the hydrophobic residues by hydrophilic ones has been
shown to improve the in vivo folding properties of the protein (Nieba et al., 1997).
The disulfide bonds of antibodies make a significant contribution to the stability
of the structure and are therefore conserved in evolution. In some cases,
however, it is possible to replace the disulfide-forming cysteines with other amino
acids and still obtain active and correctly folded antibody fragments (Wörn and
Plückthun, 1998). Disulfide-free functional antibodies (intrabodies), which can be
produced in the reducing environment of the cytoplasm, are of increasing interest
because they can be targeted to bind and inactivate cellular components (for
reviews, see Richardson and Marasco, 1995; Cattaneo and Biocca, 1999).
1.2.2 Fab fragments
Although functional Fab fragments can be produced proteolytically from the
parental antibody, bacterial expression provides a convenient source of large
amounts of relatively homogenous protein preparation. Bacterial expression
systems have been applied to produce Fab fragments originating from different
antibody classes including IgG (Better et al., 1988; Hemminki et al., 1995), IgM
(Hay et al., 1992; Adib-Conquy et al., 1995; Jahn et al., 1995) and IgE
(Steinberger et al., 1996). In the case of IgM Fab fragments the production
levels have been relatively low, most probably due to problems observed in the
production of the Fd chains (Abid-Conquy et al., 1995; Jahn, et al., 1995). It has
also been reported that the constant domains of the Fd and L chains may have a
significant effect on the amount of functional Fab fragments produced in E. coli
(MacKenzie et al., 1994; Pajunen et al., 1997).
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The antigen binding properties of recombinant Fab fragments have been
reported to be comparable to (Better et al., 1988; Anand et al., 1991; Hemminki
et al., 1998a) or in some cases slightly decreased (Pajunen et al., 1997)
compared to the proteolytically produced corresponding Fab fragments.
Compared to intact antibody molecules Fab fragments, which lack the Fc
portion, may offer potential advantages in therapy trials due to their lower
immunogenity and better pharmacokinetic properties (Yokota et al., 1992;
Colcher et al., 1998). In addition the use of Fab fragments rather than the
complete antibody in diagnostic immunoassays may decrease unwanted
interferences sometimes observed in the assays (Kato et al., 1979; Vaidya and
Beatty, 1992). Retaining of the CH1 and CL domains makes it possible to further
engineer the fragment without affecting those parts directly involved in the
antigen binding. For example, it is possible to introduce appropriate amino acid
residues into the constant domains to improve labelling properties of the
fragment for sensitive immunoassay applications (Hemminki et al., 1995).
1.2.3 Single-chain antibodies
The smallest functional antibody fragment, which maintains the complete
antigen binding site, is the Fv fragment (Fig. 2). This fragment is a non-covalent
heterodimer composed of the VH and VL domains (Skerra and Plückthun, 1988).
Active Fv fragments have been produced by proteolytic digestion of the
antibody molecule (Hochman et al., 1973). However, the proteolysis often does
not result in a homogeneous population of Fv fragments but rather produces a
number of partially digested protein molecules, which may hamper both
purification and characterization. Therefore, the antibody engineering approach
provides a more efficient and generally applicable method to produce Fv
fragments. However, usefulness of the Fv fragments is limited by dissociation of
the V domains at low protein concentrations and in the absence of antigen
(Glockshuber et al., 1990; Jäger and Plückthun, 1999). To stabilize the Fv
structure the VH and VL domains have been linked either chemically
(Glockshuber et al., 1990) or by disulfide bonds (Glockshuber et al., 1990;
Brinkmann et al., 1993; Reiter et al., 1996). An alternative method is to connect
the V domains with a flexible linker peptide so that the antigen binding site is
regenerated in a single-chain antibody molecule, scFv (Fig. 2) (Bird et al., 1988;
Huston et al., 1988). The order of the domains can be either VH-linker-VL or VL-
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linker-VH and both orientations have been applied (reviewed by Huston et al.,
1991, 1995).
The length of the linker peptide used to join the V domains is crucial in the
folding of the polypeptide chain. It has been estimated that the linker peptide
must span at least 3.5 nm (35Å) between the C-terminus of one V domain and
the N-terminus of the other V domain without affecting the ability of the
domains to fold and form an intact antigen binding site (Huston et al., 1991). A
further evaluation based on calculations using computer-generated scFv
structures has shown that the distance between the V domains in the VL-VH
orientation is always 5–10 Å greater than in the VH-VL orientation (Huston et al.,
1995). Consequently, the use of the same linker may lead to functional
differences between the two scFvs molecules with opposite V domain order. The
length of the linker most commonly applied varies between 12 and 18 amino
acids (for reviews, see Huston et al., 1991, 1995) but also up to 30 residues long
linkers have been used (Desplancq et al., 1994; Nieba et al., 1997). Use of very
short linker prevents pairing of the VH domain to its attached VL domain and
instead forces pairing with counterpart domains of another molecule to form
bivalent dimers (Holliger et al., 1993; Atwell et al., 1996) and higher multimers
(Desplancq et al., 1994; Whitlow et al., 1994). Further, the monomeric and
dimeric forms are in a concentration-dependent equilibrium; in dilute solutions
only monomers are present (Desplancq et al., 1994; Whitlow et al., 1994).
Atwell et al. (1999) showed that linkers of three amino acid residues in length
are needed to form dimers, whereas a linker with two residues or less induces
formation of trimers.
In addition to the length, the amino acid composition of the linker also has a
crucial role in the design of a viable linker peptide. The sequence should be
hydrophilic to prevent intercalation of the peptide within or between the V
domains during protein folding. Nowadays, the most frequently used linkers
consist primarily of repeats of glycine (G) and serine (S) residues (GGGGS), in
which serine provides hydrophilicity and glycine confers flexibility to the
peptide backbone (Huston et al., 1988; Huston et al., 1991). In addition to the
linker peptides designed de novo, peptide sequences from known proteins have
been applied (Bird et al., 1988; Takkinen et al., 1991; Smallshaw et al., 1999).
Functional linkers can also be selected from a large population of peptide
candidates. Stemmer et al. (1993) constructed a single-chain antibody gene
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library with randomized linker sequences and could select an scFv showing
antigen binding affinity comparable to that of the parental antibody. Recently,
phage display library technology combined with random mutagenesis was
shown to be a potential method to isolate optimized linker peptides for scFvs
(Tang et al., 1996; Turner et al., 1997; Hennecke et al., 1998).
Single-chain antibodies produced in bacteria have often been shown to have
antigen binding properties similar to those of the parental monoclonal antibody
or the corresponding Fab fragment (Colcher et al., 1990; Takkinen et al., 1991;
Smallshaw et al., 1999). It has also been observed that the proteolytic stability of
an scFv fragment depends on the linker peptide sequence (Whitlow et al., 1993).
Recently, Sieber et al. (1998) developed a phage display method, which links the
protease resistance of a protein with the infectivity of the filamentous phage. In
this strategy a proteolysis step is included in the selection allowing isolation of
proteins with improved conformational stability. The stability of scFvs against
thermal and pH denaturation has been demonstrated to be slightly reduced
compared to that of the parental monoclonal antibody and/or the corresponding
Fab fragment (Takkinen et al., 1991; Smallshaw et al., 1999). By using phage
display under different selection pressures such as elevated temperatures or in
the presence of denaturating compounds it is possible to create single-chain
antibodies with improved stability (Jung et al., 1999).
1.2.4 Multivalent antibodies
Antibodies are multivalent molecules, which can bind simultaneously to two or
more antigen molecules. This multivalent nature of antibodies provides a high
degree of functional affinity (avidity) compared to monovalent antibody fragments
and improves the performance of antibodies both in vivo and in vitro. This
increase in functional affinity is seen in reduced dissociation rates, which result
from multiple binding to two or more target antigen molecules. Recently, small
bi- or multivalent antibody fragments have aroused much interest in tumor
imaging and therapy (for reviews see, Adams and Schier, 1999; Hudson, 1999;
Hudson and Kortt, 1999). The gain in the functional affinity through multivalent
binding depends on a number of factors including the density, spatial
arrangement and accessibility of the antigen/epitope on the surface (Plückthun
and Pack, 1997). In addition, the antigen binding sites of the multivalent
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fragment should be flexible enough to allow numerous binding or cross-linking
geometries at the same time.
There are several possibilities for generation of multivalent antibodies, some of
which are presented below (for reviews, see Hudson and Kortt, 1999; Little et
al., 2000). The simplest way to produce bivalent antibodies is to utilize the
tendency of scFvs to self-associate spontaneously. While relatively stabile non-
covalent dimers can be obtained in some cases, this method usually produces a
mixture of monomers and dimers and is limited to those scFvs having the
capacity to form homodimers spontaneously. The dimerization process can be
promoted by connecting the V domains with short linker peptides, which drive
the transition from monomers to dimers (diabodies) (Holliger et al., 1993). It has
been shown that using linkers of between three and five residues only diabodies
are formed, whereas trimers (triabodies) and even tetramers (tetrabodies)(Fig. 4)
can be produced with linkers containing less than three amino acids (Iliades et
al., 1997; Kortt et al., 1997; Le Gall et al., 1999; Dolezal et al., 2000). These
high-avidity antibodies can be produced as functional antigen binding molecules
into the bacterial periplasm (Power and Hudson, 2000). The flexibility and
orientation of the antigen binding sites in diabodies and triabodies have been
confirmed by electron microscopy (Lawrence et al., 1998, Atwell et al., 1999).
Figure 4. Multivalent recombinant antibody fragments. See text for details.
Diabody
Triabody
Tetrabody
Bivalent miniantibody Tetravalent miniantibody
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An alternative approach to increase the functional affinity is to fuse scFv
fragments genetically with protein dimerizing motifs to produce
"miniantibodies" (Fig. 4). For example, a sequence of an amphiphilic helix has
been connected via a flexible hinge from mouse IgG3 to the C-terminus of an
scFv molecule to produce bivalent scFv fragments (Pack and Plückthun, 1992;
Pack et al., 1993). These bivalent miniantibodies were secreted as functional
proteins to the periplasmic space of E. coli and produced in large scale using
high-cell density fermentation (Pack et al., 1993). Assembly of functional
bivalent miniantibodies was also demonstrated for an scFv fused to the human
IgG1 CH3 domain, which in an intact IgG1 molecule promotes and stabilizes
dimerization of the H chains (Hu et al., 1996).
In addition to bivalent antibodies tetravalent miniantibodies (Fig. 4) with higher
functional affinity have also attracted increasing interest in cancer therapy
(Plückthun and Pack, 1997; Hudson, 1998, 1999). These antibody molecules
have been generated by fusing the scFv to either tetramerizing helix (Pack et al.,
1995), tetramerization domain of the human transcription factor p53
(Rheinnecker et al., 1996) or to core-streptavidin (Kipriyanov et al., 1996).
1.2.5 Bispecific antibodies
Bispecific antibodies incorporate the binding specificities of two different
antibodies into a single molecule and, therefore, they are structurally bivalent but
functionally univalent for each antigen-binding specificity (Fig. 2). These
molecules have potential applications in cancer therapy and treatment of
infectious disease (reviewed in Segal et al., 1999; van Spriel et al., 2000). For
example, bispecific antibodies can be designed to bind both to the target cells
(tumors or pathogens) and to the effector cells (e.g. T cells, natural killer cells
and macrophages) as an approach to utilize cellular immune defense
mechanisms to destroy the target cells (Holliger et al., 1996, 1999; Manzke et
al., 1999). In addition to therapeutic applications, the dual binding specificity
can also be employed in various immunochemical assays, including microtitre
plate assays, immunoblotting and immunohistochemistry (Kontermann et al.,
1997). One of the binding arms can be designed to bind to the target antigen and
the other arm to the marker enzyme or another indicator molecule. This
arrangement allows co-incubation of the antibody and the marker molecule and
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thus simplifies the performance of the assay. As an approach to enhance the
binding affinity of the antibody in immunoassays or to improve tumor targeting
and retention, bispecific antibodies can also be designed to bind to two non-
overlapping epitopes on the same target molecule (Cheong et al., 1990; Robert
et al., 1999).
Bispecific antibodies have been produced by fusion of two hybridomas (Milstein
and Cuello, 1983) or by chemical crosslinking of two IgGs with different
specificities (Karpovsky et al., 1984) or Fab fragments (Cheong et al., 1990;
Robert et al., 1999). Recently, a "knobs-into-holes" strategy was introduced to
facilitate heterodimerization between two different antibody H chains co-
expressed in mammalian cells (Ridgway et al., 1996). In this method knob
structures were obtained by replacing at the CH3 domain small amino acids with
larger ones in one chain whereas on the other chain holes were created by
replacing large residues with small ones.
Antibody engineering has led to the development of new bispecific antibody
formats. Bispecific diabodies are recombinant constructs comprising two scFvs,
VHA-L-VLB and VHB-L-VLA, derived from parent antibodies with specificities
A and B, where L is a short linker peptide (Holliger et al., 1993; Whitlow et al.,
1994; Atwell et al., 1996). Coexpression of these two polypeptides in a same
bacterial cell results in their secretion and non-covalent association to form a
functional molecule with both binding specificities. Further, it was demonstrated
that good yields (up to 935 mg/l) of bispecific diabodies can be obtained by
using high cell density fermentation (Zhu et al., 1996). Compared to IgG or
antibody fragments in which the two binding sites are rather flexible, the
structure of the diabody is more rigid and compact with the antigen binding sites
at the opposite ends of the molecule (Perisic et al., 1994).
Alternatively, bispecific antibodies have been constructed by joining "in tandem"
two different scFvs together by a polypeptide linker (Fig. 2) (Gruber et al., 1994;
Mallender and Voss, 1994; de Jonge et al., 1995). These antibody fragments
were secreted as inclusion bodies into the periplasmic space of E. coli and could
after refolding be obtained as active antigen binding proteins. Müller et al.
(1998a) constructed bispecific miniantibodies in which the CH1 domain fused to
the C-terminus of an scFv specific for epidermal growth factor receptor while
the CL (kappa) domain was fused to the C-terminus of a CD2 specific scFv.
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Bispecific antibodies, heterodimerized via a disulfide bridge between the C
domains, could be produced in E. coli. Further, by linking of two different scFvs
with a helical dimerizing domain it is possible to produce miniantibodies with
two valencies for each specificity (Müller et al., 1998b).
1.2.6 Bifunctional antibodies
Bifunctional antibodies are molecules in which whole antibody molecules or
their antigen binding domains have been fused to other functional molecules
such as drugs, toxins or enzymes (Fig. 2). For example, recombinant
immunotoxins are targeted drugs in which a protein toxin or its effector
fragment has been fused to an antibody (reviewed in Kreitman, 1999). Ideally an
immunotoxin is capable of killing the target cell efficiently while causing little
or no harm to other tissues. Functional recombinant immunotoxins recognizing
tumor cells have been expressed in E. coli (Chaudhary et al., 1989, 1990;
Chowdhury et al., 1998; Klimka et al., 1999). In these particular cases scFv
molecules were fused to bacterial Pseudomonas exotoxin A or its truncated
mutant, which inhibits protein synthesis and causes death of the target cell.
Goyal and Batra (2000) constructed an immunotoxin by fusing the fungal toxin
restrictocin to an scFv specific for human transferrin receptor and linking these
molecules with a proteolytically cleavable peptide to enhance the cell-killing
activity of the molecule. Immunotoxins in which the VH-VL heterodimer has
been stabilized by disulfide bonds were shown in some cases to be more stable
than scFvs (for reviews, see Reiter et al., 1996; Reiter and Pastan, 1998).
Innovative improvements to the concept of using specific targeted immunotoxins
in therapy include so-called antibody-directed enzyme prodrug therapy. In this
strategy an enzyme linked to a tumor-specific antibody is first administered,
followed by administration of a non-toxic prodrug (Bhatia et al., 2000). The
prodrug is then converted at the tumor site into a cytotoxic drug by the pre-
localized enzyme. Antibody fragments can also be armed with radionuclide
chelating agents to provide tools for imaging and radioimmunotherapy (Wu and
Yazaki, 1999; Wu et al., 2000).
Recombinant antibodies fused to enzymes such as alkaline phosphatase supply a
reagent source for different applications including immunohistochemistry (Wels
et al., 1992) and different immunoassays (Carrier et al., 1995). For purification
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and detection purposes antibody fragments can be fused to the IgG binding
domain of Staphylococcus aureus protein A (Tai et al., 1990; Gandecha et al.,
1992) or the maltose-binding protein of E. coli (Brégégère et al., 1994). Further,
when an scFv was fused to a cellulose-binding domain (CBD) of a fungal or
bacterial cellulase the fusion protein obtained retained its hapten binding activity
(Reinikainen et al., 1997). Linkage of an antibody fragment to a CBD allows
immobilization to cheap and versatile cellulose matrices, which could be
exploited to develop large scale industrial affinity purification schemes (Linder
et al., 1998).
1.3 Applications of recombinant antibodies
Since the advent of hybridoma technology the exquisite specificity of
monoclonal antibodies has been exploited for a number of applications in
diagnostics, medicine and basic research. The development of antibody
engineering technology together with the microbial expression systems now
available provide tools to design and produce novel and tailored antibodies at
affordable prices, even for large-scale applications. Furthermore, purification of
antibody fragments can be greatly facilitated by linking tags or peptides to these
molecules, which allows production of homogenous, well-defined and active
preparations.
1.3.1 Immunodiagnostics
Current immunoassays mainly utilize monoclonal antibodies. In some cases,
however, production of monoclonal antibodies with sufficient specificity and
affinity by hybridoma technology has not been successful. During recent years,
tailor-made recombinant antibody fragments produced in bacteria have become
potential alternatives to these "conventional" reagents. Nowadays, antibody
fragments for virtually any antigen can be isolated from large naive libraries,
thus avoiding the necessity for immunization of animals (Marks et al., 1991;
Hoogenboom et al., 1998).
The functionality of recombinant antibodies as immunological reagents has been
demonstrated in a number of different assay formats (Kontermann et al., 1997;
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Lindner et al., 1997; Emanuel et al., 2000). By using modern antibody
engineering it is possible to manipulate and further improve the properties of
these antibodies to meet the demands of the assay under consideration. It has
been shown that the labelling efficiency of a recombinant Fab fragment by
europium (Eu3+) chelate derivative often applied in fluoroimmunoassays can be
significantly improved by increasing the number of the lysine residues at the
surface of the L chain constant domain (Hemminki et al., 1995). Further, Fab
fragments have been labelled with biotin by fusing the Fd chain to a 13 amino
acid acceptor peptide and performing the site-specific biotinylation enzymatically
in vitro with E. coli biotin holoenzyme synthetase (BirA) (Saviranta et al., 1998).
In another approach the Fd chain was fused with E. coli biotin carboxy carrier
protein and biotinylation was accomplished in vivo by Bir A overexpressed in
bacteria (Sibler et al., 1999). In addition to antibody labelling, modern
engineering technology also provides excellent tools to improve or refine
binding properties of antibodies. Especially it can provide a useful tool in those
cases in which conventional methods have not provided antibodies with
sufficiently high affinity and specificity. This has been demonstrated for
testosterone specific Fab fragment, the specificity and affinity of which were
significantly improved by random mutagenesis combined with phage display
(Hemminki et al., 1998a and b). In another case a high affinity oestradiol
specific scFv with simultaneously decreased cross-reactivity to related steroids
could be isolated from a large repertoire of antibody fragments displayed on
phage (Pope et al., 1996).
Recently, a sandwich-type enzyme-linked immunosorbent (ELISA) assay was
developed based on scFv fusion proteins for both capture and detection of a
plant pathogen (Kerschbaumer et al., 1997). The wells were coated with a
miniantibody carrying a dimerizing motif and the antigen was detected by scFv-
AFOS fusion. The assay was reported to be more sensitive than a conventional
ELISA based on polyclonal antisera, partly due to the good coating properties of
the miniantibody. In another study a dual-label time-resolved immunofluorometric
assay based on recombinant Fab fragments was set up to measure both free and
total prostate-specific antigen (Eriksson et al., 2000). The performance of this
assay format was tested with clinical samples and was found to be comparable to
a conventional assay based on monoclonal antibodies. Furthermore, a sample
which gave a false positive result in the conventional assay probably due to
interference caused by the Fc part, was undetectable in the Fab-based assay,
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which demonstrates the potential of antibody engineering in establishing new
immunoreagents.
1.3.2 Therapy
Mouse monoclonal antibodies, as well as chimerized and humanized derivatives
of these, have shown therapeutic potential, and in recent years several of them
have been approved for clinical use (reviewed in Glennie and Johnson, 2000).
Although good performance has been observed in several cases, especially with
humanized molecules, the widespread use of these antibodies as therapeutic
agents has been limited by their immunogenicity. Over the past decade,
molecular display technologies have been developed which allow generation of
fully human antibodies (Marks et al., 1991; Vaughan et al., 1996, 1998).
Further, scaling up of the microbial production system provides large amounts of
antibody fragments, which can be efficiently purified even for clinical studies
requiring particular precautions (Casey et al., 1995).
Small antigen binding molecules such as Fab and scFv fragments offer several
advantages over a whole antibody molecule in therapeutic applications (for
reviews, see Colcher et al., 1998; Adams and Schier, 1999; Hudson, 1999). Due
to their reduced size these molecules penetrate more rapidly and evenly into
tumors and other tissues compared to the whole antibodies (Yokota et al., 1992;
Colcher et al., 1998). Since the antibody fragments have more rapid clearance
from the blood, drugs and radionuclides can be coupled with reduced risk of
toxic effects in normal tissues (Colcher et al., 1990; Wu and Yasaki, 1999).
Comparison of mutant scFvs with different affinities has shown that increased
affinity significantly improves tumor targeting and leads to longer retention of
the fragment in tumors (Neri et al., 1997; Adams et al., 1998; Viti et al., 1999).
On the other hand, extremely high-affinity antibodies designed to target solid
tumors may be bound in an irreversible manner to the first target antigen
encountered, which may hamper further penetration of the antibodies into the
tumor tissue (Adams and Schier, 1999). One limitation of using the scFv and
Fab formats for targeting in vivo is their monovalent binding to antigen. The
efficiency of tumor targeting can be improved by using multivalent antibody
fragments (Adams et al., 1993; Neri et al., 1997; Colcher et al., 1998; Viti et al.,
1999).
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Hitherto, therapeutic trials of bispecific antibodies composed of whole antibody
molecules have been limited owing to their toxicity observed in initial trials as
well as to the high cost of producing these molecules for clinical evaluation
(reviewed in Segal et al., 1999; van Spriel et al., 2000). Recently small
bispecific antibodies produced in bacteria have been shown to be functional
immunotherapeutic agents for tumor treatment in vivo (de Jonge et al., 1998;
Cochlovius et al., 2000) and may thus allow to overcome these problems in the
future. Several different recombinant immunotoxins have also been produced
and shown to be potent antitumor agents producing tumor regressions (Kreitman
et al., 1994; Siegall, et al. 1994; Chowdhury et al., 1998). Although some
recombinant immunotoxins are currently in clinical trials (Reiter and Pastan,
1998; Kreitman, 1999), there are still challenges to be met, including reduction
of immunogenicity and toxicity of these molecules (Kreitman, 1999).
1.3.3 Structure analysis
Antibodies are large flexible glycoproteins, which can exist in a range of
different conformations due to the intrinsic mobility of the individual domains.
This causes difficulties to obtain high quality crystals for structure analysis and
only a few crystal structures of intact antibodies have been solved (Harris et al.,
1997, 1998). Reduction of antibody size by omitting the Fc part and the flexible
hinge region increases the probability of obtaining crystals showing high
resolution diffraction. Further, the smaller size of the antibody fragments makes
it possible to crystallize them when complexed with antigens, and the detailed
three dimensional structure obtained can be used to identify amino acid residues
important for binding. A number of antibody fragments have been crystallized
and structures determined with and/or without antigen, including Fab fragments
(Whitlow et al., 1995), scFvs (Malby et al., 1993, 1998; Zdanow et al., 1994)
and Fv fragments (Bhat et al., 1994; Fields et al., 1996). The crystal structure
obtained for one diabody revealed that the molecule had a rigid structure with
the antigen binding sites at opposite ends of the molecule (Perisic et al., 1994).
Further, the distance between the antigen binding sites was measured to be 65Å,
which is less than half the estimated distance in an IgG molecule. Determination
of the crystal structure of a triabody revealed that in this trimeric antibody the
three antigen binding sites were arranged in a cyclic head-to-tail manner (Pei et
al., 1997). In addition to X-ray crystallography, NMR spectroscopy has also
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been used in structural studies of antibodies (McManus and Riechmann, 1991;
Freund et al., 1993).
A novel approach in determination of the crystal structures of membrane
proteins is to use small antibody fragments in the co-crystallization of these
macromolecules. Membrane proteins and their complexes are poorly soluble in
aqueous environment and need detergents for solubilization. Most of the crystal
lattice contacts are made by the polar extramembranous parts of the membrane
protein. Binding of an antibody fragment to a membrane protein increases the
polar area and thus increases the possibility to obtain well-ordered crystals for
structure determination (Ostermeier et al., 1995). Fv fragment-mediated
crystallization has successfully been applied for X-ray analysis of bacterial
cytochrome c oxidase, which is a multisubunit complex (Iwata et al., 1995;
Ostermeier et al., 1995, 1997). The cytochrome c oxidase complex was purified
to homogeneity in one step procedure on an Fv fragment-based column and
eluted directly as an Fv-cytochrome complex (Kleymann et al., 1995). Recently,
the cytochrome bc1 complex from the yeast Saccharomyces cerevisiae was
crystallized together with an Fv fragment (Hunte et al., 2000).
1.4 Display technology
During recent years a number of different display technologies have been
developed for enriching molecular diversity and producing novel types of
proteins (for a review, see Li, 2000). Antibodies have been expressed on the
surface of different microorganisms including bacteriophages (bacterial viruses),
viruses, bacteria and yeast. All these systems share the principle of a linkage
between genotype (the Ig genes) and phenotype (antigen-binding). This linkage
allows isolation of a protein with desired binding properties from a large pool of
non-binding antibodies, while the genetic material remains within the
microorganism and is thus available for isolation and further engineering. In the
future, recombinant antibodies and large antibody libraries containing binders
virtually to any target antigen may become important tools in functional
genomic and proteomic research (Borrebaeck, 1998; Holt et al., 2000).
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1.4.1 Phage display
About fifteen years ago Smith (1985) first demonstrated that foreign DNA
fragments can be fused to the gene III coding for pIII coat protein of a non-lytic
filamentous phage and expressed as a fusion protein on the virion surface
without destroying the infectivity of the phage. Thereafter McCafferty et al.
(1990) demonstrated that an scFv fragment can be displayed as an active antigen
binding domain on the surface of filamentous phage and that rare clones can be
isolated from a large population by using antigen to select and screen the phage.
Since these first applications, the technology has been extended to other
antibody molecules including Fab fragments (Barbas et al., 1991; Hoogenboom
et al., 1991; Kang et al., 1991), disulfide-stabilized Fv fragments (Brinkmann et
al., 1995) and diabodies (McGuinness et al., 1996).
Antibody libraries are constructed by cloning PCR amplified antibody gene
repertoires into a phage or phagemid vector, which allows display of the
antibodies on the phage particle (for reviews, see Hoogenboom et al., 1992;
Winter et al., 1994). The Ig gene repertoire can be cloned from stimulated B
cells (high levels of mRNA) after immunization (Clackson et al., 1991; Persson
et al., 1991) or viral infection (Burton et al., 1991). This approach results in
higher frequency of binders specific for the antigen, and due to the in vivo
affinity maturation of the antibodies the isolated binders usually have high
affinities. Alternatively, antibody gene repertoires can be isolated from non-
immunized individuals by PCR amplification of the heavy chain genes from IgM
and the light chain genes from κ and λ cDNA (Marks et al., 1991). The IgM VH
repertoire is generally more diverse than the IgG VH repertoire because it
represents the entire B cell population, which has not undergone selection and
amplification by the antigen. Basically, these non-immunized or "naive"
antibody libraries can be repeatedly used for selection of antibodies with new
specificities without the need to construct a new library for each antigen. The
affinities of antibodies derived from such naive repertoires containing 107–108
individual clones are in the micromolar range (Marks et al., 1991; Griffiths et
al., 1993). However, by constructing very large non-immunized libraries of
about 1010 individual clones, antibodies with subnanomolar affinities have been
isolated (Vaughan et al., 1996; Sheets et al., 1998; de Haard et al., 1999). A
third approach is to use synthetically assembled variable regions to construct
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synthetic antibody gene libraries, which provides high structural diversity
(Barbas et al., 1992; Hoogenboom and Winter, 1992; Griffiths et al., 1994).
To express antibody fragments on the surface of filamentous bacteriophage the
Ig genes can be fused either to the VIII gene (Kang et al., 1991) or the III gene
(McCafferty et al., 1990) (Fig. 5). The major coat protein pVIII is present with
Figure 5. Schematic figure showing the display of Fab fragments as pIII and
pVIII fusions on the surface of bacteriophage.
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about 2700 copies on the phage particle and fusion to antibody results in
multivalent display of the fragment. The minor coat protein pIII is present with
between three and five copies at one tip of the phage and is needed for bacterial
infectivity. By far the most extensively used display format is based on the use
of phagemid vector and the pIII display, which allows high frequency of
monovalent display and thus is preferred in selection for affinity (reviewed in
Hoogenboom et al., 1998; Hoogenboom and Chames, 2000).
Selection of an antibody from the phage display library includes sequential
enrichment of specific binding phage from a huge number of nonspecific phage
particles. This is achieved by multiple rounds of phage binding to the antigen,
washing to remove nonspecific phage and elution to rescue the specifically
binding phages. After each round the eluted phages are amplified by infection of
E.coli for the next round of selection. After the last round of the selection
procedure, soluble antibodies are produced in bacteria and characterized. There
are several different selection strategies that can be used to obtain specific
antibodies (for reviews, see Hoogenboom et al., 1998; Hoogenboom and
Chames et al., 2000). For most applications selection can be performed simply
by incubating phage on antigen immobilized onto a solid support, such as
immunotubes (Marks et al., 1991; Griffiths et al., 1993), microtitre plate wells
(Burton et al., 1991; Hemminki et al., 1998 a and b), BIAcore sensor chips
(Malmborg et al., 1996; Schier and Marks, 1996) or columns (McCafferty et al.,
1990; Marks et al., 1991). Alternatively, the phage library can be incubated with
the biotinylated antigen in solution, followed by capture of the antigen-phage
complex on streptavidin surface (Hawkins et al., 1992; Griffiths et al., 1994).
This approach can be used to select antibodies on the basis of affinity by using
an antigen concentration significantly less than the desired dissociation constant
Kd (Hawkins et al., 1992; Schier et al., 1996a; Hemminki et al., 1998b). Further,
by choosing an appropriate design of the selection procedure, antibodies can also
be selected on the basis of kinetic properties (Hawkins et al., 1992; Duenas et
al., 1996), improved specificity (Hemminki et al., 1998b) or phage infectivity
(Krebber et al., 1995; Hennecke et al., 1998). In cases in which pure antigen is
not available (e.g. integral membrane protein) or the antigen is unknown (e.g.
when searching for new markers on cells or tissues), specific antibodies must be
isolated using more complex sources, such as whole cells (Marks et al., 1993; de
Kruif et al., 1995; Klimka et al., 1999) or tissue fragments (van Ewijk et al.,
1997).
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The binding characteristics of antibodies isolated from phage libraries are often
sufficient for their use in research applications, such as ELISA, Western blotting
or immunofluorescence (Nissim et al., 1994; Lindner et al., 1997). However, the
affinity or specificity of antibodies selected from the libraries may not be high
enough for diagnostic or therapeutic applications and thus further improvement
is required. The affinities of antibody fragments can be improved by targeting
mutagenesis to one or more of the CDRs or only a part of them followed by
selection of high affinity antibodies (Hawkins et al., 1992; Schier et al., 1996b;
Thompson et al., 1996; Hemminki et al., 1998b; Chowdhury and Pastan, 1999).
Further, mutagenesis of the CDRs and careful design of the selection methods
have been used as a successful approach to increase the specificity of antibodies
(Hemminki et al., 1998a). In addition to mutagenesis, pairing of a particular
heavy chain with a library of light chains ("chain-shuffling"), or vice versa, has
been used to increase the affinity of antibodies (Marks et al., 1992; Pope et al.,
1996; Schier et al., 1996a). The binding affinities achieved in vitro have been in
the nanomolar or picomolar range.
Phage display technology has revolutionized the way in which we can generate
new specific antibodies without immunization, and thus enables production of
antibodies which have been difficult or impossible to obtain by conventional
methods based on immunization, such as human antibodies and antibodies
against self-antigens (Griffiths et al., 1993; Vaughan et al., 1996; Hoogenboom
and Chames, 2000). In addition to selection for binding properties, phage display
system can be applied to isolate stable and well-folded proteins, catalysts or
polypeptide substrates (reviewed in Forrer et al., 1999).
1.4.2 Baculovirus display
Although phage display systems have provided tools to generate specific tailor-
made antibodies for several purposes, the technology has limitations imposed by
the expression host. Phages are prokaryote viruses, and proteins intended for
display must be suitable for secretion from a prokaryotic host such as E. coli and
must not be dependent on eukaryotic post-translational modifications or folding
requirements. Therefore, for such proteins a eukaryotic viral system capable of
displaying complex eukaryotic proteins would be useful. Recombinant
baculoviruses are nowadays widely used for high-level expression of
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heterologous genes providing a eukaryotic processing environment. In addition,
baculoviruses have proved to be powerful tools to investigate viral assembly
processes and may provide a valuable approach in the development of new
vaccines and gene deliver vehicles (for reviews, see Possee, 1997; Verma et al.,
1998; Kost and Condreay, 1999).
Baculoviruses are a large family of double-stranded DNA viruses that infect
only invertebrates, usually insects. During their infection cycle baculoviruses
produce two structurally and functionally distinct virion phenotypes (Blissard
and Rohrmann, 1990). One form is budded virus (BV), which is produced by
budding from the surfaces of infected cells. The BV virions transmit cell-to-cell
infection within the animal, and are highly infectious for tissues of the host and
for cultured insect cells. The other phenotype, occlusion derived virus (ODV), is
found within protective occlusion bodies in the host cell nucleus and is able to
transmit infection from host to host by the oral route. Although the two different
virus phenotypes (BV and ODV) share some common structural components,
there are some components that are specific for each phenotype (reviewed in
Rohrmann, 1992). One of these is the structural transmembrane protein gp64,
which is the major envelope glycoprotein of the BV form and is used as a fusion
partner to express proteins on the viral surface. The BV gp64 protein has been
shown to be essential for the infectivity and it mediates the membrane fusion in
a pH-dependent manner (Blissard and Wenz, 1992; Monsma et al., 1996). It is
abundantly expressed on the plasma membrane of infected cells and is present
on the virions as homo-trimers (Oomens et al., 1995). The gp64 protein is
incorporated into newly formed BVs when nucleocapsids containing the viral
DNA bud through the host plasma membrane. gp64 has two functional domains,
the oligomerization domain and the fusion domain (Monsma and Blissard,
1995). The oligomerization domain within an amphipathic helix was thought to
be responsible for oligomerization (or trimerization) and transport of the
molecule (Fig. 6). The fusion domain containing a cluster of hydrophobic amino
acids was suggested to be involved in the fusion of the virus into the plasma
membrane.
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Figure 6. A schematic presentation of the predicted structure of AcNPV gp64
protein containing the signal peptide (SP), fusion domain (FD), oligomerization
domain (OD), transmembrane domain (TM) and cytoplasmic tail domain (CTD).
ψ denotes predicted N-linked glycosylation sites (modified from Monsma and
Blissard, 1995; Oomens and Blissard, 1999).
Autographa californica nuclear polyhedrosis virus (AcNPV) has been used as an
alternative for protein display in a eukaryotic system. Boublik et al. (1995) were
the first to show that foreign proteins, glutatione-S-transferase and gp120 (the
HIV major surface glycoprotein), could be fused to gp64 and displayed on the
surface of a baculovirus particle. Further, they localized the position where
insertions would be tolerated and demonstrated that a foreign sequence cloned in
frame between the signal peptide and the sequence encoding the intact gp64
protein resulted in expression of a stable and functional protein on the virion
surface. The same approach was taken by Mottershead et al. (1997), who
demonstrated expression of green fluorescent protein and two rubella virus
envelope proteins, E1 and E2, on the baculovirus surface. Grabherr et al. (1997)
fused ectodomain of the glycosylated HIV-1 envelope protein gp41 both to the
entire gp64 and its membrane anchor domain and found increased surface
expression level of the foreign protein with the truncated gp64 fusion. A recent
study by Ernst et al. (1998) demonstrated the applicability of baculovirus display
technology for the construction and screening of eukaryotic expression libraries.
They inserted derivatives of the HIV-1 gp41 epitope "ELDKWA" binding to a
neutralizing human antibody into the antigenic site B of influenza virus
hemagglutinin expressed on the surface of baculovirus-infected cells. By using
fluorescence activated cell sorting (FACS) to screen the cells with a specific
neutralizing antibody they were able to isolate a baculovirus clone with
increased antibody binding activity. As an approach to modify the native gp64
protein without disturbing viral infectivity, short peptide coding sequences were
inserted into the gp64 coding sequence utilizing a naturally occurring restriction
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enzyme site (Ernst et al., 2000). Expression of these peptides as part of the gp64
envelope protein resulted in production of viable recombinant virus particles
showing titers comparable to that of the wild-type virus. This approach allowed
insertion of the peptide to every single copy of the gp64 protein resulting in high
avidity display of the molecule. Lindley et al. (2000) fused the human nuclear
receptors LXRβ and FXR to the N-terminus of the gp64 protein and used the
baculovirus virions displaying the receptor proteins as immunogens to produce
monoclonal antibodies. This strategy provided a novel alternative means to
generate antibodies without the need for purification of the immunogen.
 In addition to AcNPV, other viruses have also been investigated as a basis for a
viral eukaryotic display system, including sindbis virus (London et al., 1992),
poliovirus (Rose et al., 1994) and hepatitis B virus (Kratz et al., 1999). In
addition, retroviruses have been employed for functional display of single-chain
antibodies on the surface of virions, which may allow more specific targeting of
viral vectors for therapeutic purposes (Russell et al., 1993; Konishi et al., 1998).
1.4.3 Other display systems
Display of heterologous proteins on the surface of cells provides an alternative
or complement to phage- or virus-based systems. A number of different proteins
have been expressed on the surface of both gram-negative and gram-positive
bacteria or yeast by fusing the molecules to membrane proteins or cell wall
components (for reviews, see Schreuder et al., 1996; Georgiou et al., 1997; Ståhl
and Uhlén, 1997). These nonviral microorganisms displaying foreign sequences
have several potential applications including presentation and screening of
polypeptide libraries or they might be used as whole-cell vaccines, biocatalysts
or cell-based reagents for diagnostic purposes (Schreuder et al., 1996; Georgiou
et al., 1997; Ståhl and Uhlén, 1997). Libraries propagated in the cells are limited
in size and in some cases factors such as steric interference with the native
surface molecules, susceptibility to surface proteases or conformational
constraints caused by the fusion to the carrier protein may affect the viability of
the surface displayed proteins (Georgiou et al., 1997). On the other hand
screening or sorting of the cell surface libraries by flow cytometry and FACS are
powerful methods to enrich effectively positive clones (Francisco et al., 1993;
Georgiou et al., 1997, Kieke et al., 1997). Fully functional antibody fragments
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have been displayed on E. coli surface (Fuchs et al., 1991; Francisco et al.,
1993) and, recently, antibodies with improved affinity were isolated by using
affinity selection from mutant libraries displayed on bacterial surface (Daugherty
et al., 1998, 1999) or yeast (Boder and Wittrup, 1997; Kieke et al., 1997).
Hanes and Plückthun (1997) applied an approach termed ribosome display for
cell-free selection of antibody fragments from libraries. In this system large
libraries (≥ 1012 clones, Hanes et al., 1998) with virtually unlimited diversity can
be constructed and the particular proteins are translated, displayed and selected
completely in vitro on the ribosomes. Recently, the ribosome display technology
was used to isolate antibodies with affinities in picomolar range (Hanes et al.,
2000). Because the selection of proteins in the ribosome display system is
performed in vitro, many drawbacks of the in vivo systems can be circumvented,
which may render this approach important in the future (reviewed in Schaffitzel
et al., 1999).
1.5 Immunoliposomes
Liposomes are artificial spherical vesicles which consist of a phospholipid
bilayer surrounding an inner aqueous cavity. They have found increasing interest
in different biomedical and biotechnical applications such as drug delivery, gene
therapy and immunodiagnostics. Liposomes can be further equipped with target-
specific ligands including receptors, antigens or antibodies (immunoliposomes),
which act as homing or anchoring probes. Furthermore during or after the
preparation of immunoliposomes it is possible to entrap almost any water-
soluble molecule (drugs, DNA, enzymes, fluorophores, dyes etc.) within the
internal cavity (Fig. 7).
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Figure 7. Schematic presentation of a marker or a drug molecule encapsulated
in an immunoliposome.
1.5.1 Preparation
Liposomes form spontaneously when phospholipids are dispersed into water. In
the lipid bilayer the hydrophilic polar heads of the phospholipids are exposed to
the outer and inner aqueous environment, whereas the non-polar hydrocarbon
tails are buried in the hydrophobic interior of the membrane layer (Fig. 7). The
size of the liposomes varies, and the diameter can be between 25 nm and several
micrometers. There are several well-established methods available for
Marker or drug molecules
Phospholipids Antibodies or
antibody fragments
Immunoliposome
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preparation of liposomes, which differ from each other in the way in which the
membrane components are dispersed in aqueous media (New, 1992).
Gregoriadis and Neerunjun (1975) were the first to describe specific targeting
and cellular uptake of drug-loaded liposomes coated by nonspecific adsorption
with rabbit polyclonal IgGs recognizing different types of cells both in vitro and
in vivo. Since their work a number of methods have been developed to couple
antibodies to liposomes. These methods include covalent coupling of the
antibody via thiol or amino groups to membrane lipids (Leserman et al., 1980;
Heath et al., 1981), or non-covalent methods applying the avidin (streptavidin)-
biotin interaction (Loughrey et al., 1987; Urdal and Hakomori, 1980). In
addition to intact antibodies Fab´ fragments have been covalently linked to lipid
derivatives via the free thiol group in the Fd chain, which leaves the antigen-
binding domains intact unlike in the other more random coupling methods
(Martin et al., 1981; Shahinian and Silvius, 1995). Recently, a novel method was
reported in which the DNA encoding the signal peptide and the aminoterminal
part of the major lipoprotein of E. coli (lpp) was fused to the DNA encoding an
scFv (Laukkanen et al., 1993; de Kruif et al., 1996). Expression of this fusion
construct in bacteria led to in vivo fatty acylation of the scFv. These lipid-tagged
scFvs produced in bacteria have been incorporated into lipid membranes to
construct functional liposomes (Laukkanen et al., 1995; de Kruif et al., 1996;
Kobatake et al., 1997). This approach avoids inactivation and low coupling
efficiency often encountered with chemical modification and provides a whole
arsenal of antibody engineering techniques, which enables preparation of tailor-
made immunoliposomes for different application.
1.5.2 Applications
The successful use of liposomes for drug delivery in vivo requires a combination
of prolonged presence in the circulation, specific targeting and efficient delivery
of the liposomal content into the target cells. Although immunoliposomes are
effective in specific binding to target cells in vitro, their utility for in vivo
purposes has been limited by their rapid uptake by the reticuloendothelial system
(RES) (reviewed in Gregoriadis, 1995). In earlier studies it was shown that by
the coating liposome surface with ganglioside GM1 or with amphipathic
poly(ethylene glycol) (PEG) the circulation half-life of liposomes was
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significantly increased (Allen et al., 1989). These liposomes are less susceptible
to uptake by RES, resulting in prolonged circulation time in the blood and
enhanced tumor accumulation, and are referred to as "sterically stabilized" or
"stealth" liposomes. Although the presence of PEG prolongs circulation time,
binding of the antibody to the target cell may be reduced due to the steric
hindrance caused by long PEG chains (Maryama et al., 1995). Coupling
methods developed recently allow linkage of antibodies e.g. via thioether
linkage to the terminus of a PEG chain to expose the antibody on the liposome
surface (Allen et al., 1995). These sterically stabilized liposomes show more
efficient target binding compared to those PEG-stabilized liposomes in which
antibodies are coupled directly to membrane lipids. Recently, Ishida et al. (1999)
showed a combinatorial approach to prepare a variety of immunoliposomal
drugs. They prepared IgG-PEG-lipid micelles, which can be transferred into
preformed drug-loaded liposomes in a one-step incubation. Ultimately, this
combinatorial method might be applied to prepare drugs tailored for individual
patient needs by selecting a defined antibody from a pool of antibodies and
mixing it with an appropriate formulation of drug-containing liposomes.
There are several recent in vitro and in vivo studies in which immunoliposomes
have been demonstrated to bind specifically to their targets and internalize into
the cells for delivery of the encapsulated drugs (Park et al., 1995; de Menezes et
al., 1998; Tseng et al., 1999). In addition to the targeted delivery of drugs,
immunoliposomes may enable other biomedical applications, such as gene
therapy. Liposomes intended for gene therapy may have different lipid
compositions, but typically have synthetic cationic lipids on their surface. These
cationic liposomes form complexes with negatively charged DNA via
electrostatic interactions and can mediate gene transfer into different cells
(Crystal, 1995; Park et al., 1997). Recently, Shi and Pardridge (2000)
constructed neutral sterically stabilized immunoliposomes loaded with β-
galactosidase or luciferase expression plasmid and carrying on their surface
monoclonal antibodies specific for transferrin receptor (TfR). These liposomes
were able to undergo endogenous TfR-mediated transport through the blood-
brain barrier and expression of the exogenous genes in the brain was observed.
The use of liposomes as analytical reagents in immunoassays is usually based
either on detection of the lysis of liposomes followed by release of the
encapsulated marker molecules (for reviews, see Monroe, 1990; Rongen et al.,
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1997) or on the detection of liposome-enhanced agglutination (Monroe, 1990).
Liposome-based immunoassays closely resemble the formats used in standard
immunoassays including homogeneous assays and competitive and non-
competitive heterogeneous formats. The encapsulated marker molecules (e.g.
fluorophors, chromophors or enzymes) serve as either indicators or amplifiers of
the specific immune reaction measured in the assay. Therefore it is of outmost
importance that the liposomes are stable and the leakage of the marker is kept at
minimum. Furthermore, for analytical purposes both the detection sensitivity and
a high signal-to-noise ratio are of crucial importance. For the signal
measurement, the lysis of antibody-associated liposomes can be accomplished
by adding detergent, complement, cytotoxin or certain divalent cations.
Immunoliposomes with an encapsulated fluorescent label (Kobatake et al., 1997)
or a lanthanide chelate (Laukkanen et al., 1995) have been demostrated to be
potential multivalent immunoreagents providing both high specificity and
sensitivity. Park and Durst (2000) developed a rapid field-portable colorimetric
sandwich immunoassay for detection of a food pathogen, E. coli O157:H7. In
this method a nitrocellulose strip with a zone of an immobilized pathogen-
specific antibody is inserted into a test tube containing a mixture of the test
sample and dye-loaded immunoliposomes carrying the specific antibody on their
surface. Due to capillary migration the pathogen-immunoliposome complex
reaches the antibody zone and the color density of the zone is directly
proportional to the amount of E. coli O157:H7 present in the sample.
1.6 Real-time biospecific interaction analysis
 In some cases the method chosen to characterize the binding properties of
antibodies is straightforward and depends directly on the intended application.
For example, the functionality of recombinant antibodies developed for reagents
in immunoassays should be evaluated in the relevant assay format (Kontermann
et al., 1997; Eriksson et al., 2000). Otherwise, several methods are available to
study antigen-antibody interactions. Immunoassays, mainly ELISA, have often
been employed as a first step in characterization of binding of the engineered
antibodies and is currently the most common way to screen antibody phage
libraries either by measuring binding of phages or/and the soluble antibodies
(Marks et al., 1991). Beyond screening for positive and negative clones, ELISA
may provide information on the relative binding activities of different antibodies
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(Anand et al., 1991). Friquet et al. (1985) introduced an ELISA method allowing
determination of the dissociation constant (KD) of antigen-antibody equilibrium
in solution, which has subsequently been applied to determine affinities of
recombinant antibody fragments (Adib-Conquy et al., 1995; Thompson et al.,
1996). Other methods employed to determine the affinity constant of engineered
antibodies include fluorescence quenching (Takkinen et al., 1991; Nieba et al.,
1997) and equilibrium dialysis (Pope et al., 1996). At present, however,
increasing numbers of binding studies on recombinant antibody fragments rely
on the use of surface plasmon resonance (SPR)-based biosensors, which enable a
more detailed kinetic analysis.
SPR detectors are biosensors, which measure refractive index changes in
solution close to the surface of a sensor. One of the interacting partners is
immobilized on the sensor surface while the other component is introduced on
the surface in solution. These instruments are capable of measuring the binding
reactions in real time without the need for labelling any of the interacting
partners. The first commercial SPR biosensor, BIAcore (BIAcore AB, Uppsala,
Sweden), was introduced in 1990 and thereafter five other SPR instruments have
been been launched (for a review, see Rich and Myszka, 2000). The BIAcore
biosensor can be used to characterize different properties of interacting
biomolecules including specificity, concentration, affinity, kinetics and epitope
specificity. A number of molecular interactions such as protein-protein, peptide-
protein, DNA-protein, DNA-DNA, sugar-protein and ligand-protein interactions,
can been studied by using this technology (Nagata and Handa, 2000). Recent
developments in instrumentation, experimental design and software have
significantly improved the performance of the technology (for reviews, see
Malmqvist, 1999; Rich and Myszka, 2000). High sensitivity and reproducibility
now make this technology suitable for characterization of combinatorial libraries
as well as for secondary screening of small drug leads in the pharmaceutical
industry (reviewed in Myszka and Rich, 2000). Furthermore, integration of the
biospecific interaction analysis by BIAcore with mass spectrometry makes it
possible to characterize and identify binding partners from crude samples, which
may be an applicable approach for example in proteomics (Nelson et al., 1999;
Williams and Addona, 2000).
The SPR technology as employed in the BIAcore instrumentation offers a
number of different assay formats which can be chosen on the basis of the
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information desired. It is possible to visualize the progress of antigen-antibody
binding on a computer screen as a function of time and the strength of the
binding can be expressed not only in terms of equilibrium affinity constants (Ka
or Kd) but also in terms of association (kass or kon) and dissociation (kdiss or koff)
rate constants. There are, however, several different factors that can influence
the results and careful optimization of the experimental conditions is necessary
to obtain reliable data (reviewed in Myszka, 1997). These factors include
diffusion of the molecule in solution to and away from the sensor surface as well
as rebinding to the immobilized molecule. This diffusion step can introduce a
phenomenon called mass transport limitation, which results in kass and kdiss
values that reflect diffusion rates of the molecule on and off the surface rather
that the true rate constants (Glaser, 1993). High flow rates and low surface
capacity are recommended means to avoid these problems (Myszka, 1997).
Rebinding to the molecule immobilized on the sensor surface may have a
remarkable effect on the affinity constants determined from the kass and kdiss
constants compared to the affinities determined in solution, as demonstrated by
Nieba et al. (1996). To eliminate the effects of rebinding they introduced a
competition BIAcore method, which measures equilibrium binding in solution.
This method is based on preincubation of the antibody with different
concentrations of the antigen in solution followed by determination of the
amount of the unbound antibody by BIAcore (Nieba et al., 1996; Hanes et al.,
1998).
The BIAcore instrumentation has been employed to determine affinities and
binding kinetics for recombinant antibody fragments derived from monoclonal
antibodies (Hemminki et al., 1995; Wu et al., 1996) or isolated from phage
display (Sheets et al., 1998; Chowdhury and Pastan, 1999), ribosome display
(Hanes et al., 1998) and cell display libraries (Daugherty et al., 1998). Further, it
has been used in studies of multivalent antibodies (MacKenzie and To, 1998)
and in characterization of epitope specificies of antibodies (Mao et al., 1999;
Viti et al., 1999). The biosensor also provides a means to confirm the capability
of bispecific antibodies to bind to two different antigens simultaneously (Müller
et al., 1998b; Robert et al., 1999). The versatility of this SPR technology in
antibody engineering was recently demonstrated by de Haard et al. (1999) who,
when isolating Fab fragments from a phage library, used BIAcore to screen the
binding of phages during the selection steps, to screen the isolated soluble
fragments produced in periplasmic fraction on the basis of off-rates and to
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confirm their binding specificities. Further, they also used BIAcore to determine
the concentration of Fab fragments present in the bacterial periplasm and to
calculate the kinetic constants. The principle of BIAcore analysis and
applications in antibody engineering are discussed more extensively in paper V.
1.7 Aims of the present study
The general aim of this work was to establish methods for the production and
characterization of recombinant antibody fragments. In this technical approach
the specific objectives were:
1. To study the influence of the heavy chain constant domain of a mouse Fab
fragment on functional expression in E. coli.
2. To investigate the effect of the linker length and amino acid composition on
the expression of soluble, active single-chain antibodies in E. coli.
3. To characterize binding properties of membrane-anchored, surface-
displayed recombinant antibody fragments as a model for diagnostic
applications.
4. To investigate functional antibody display on the surface of baculovirus as a
model for a eukaryotic display system.
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2. Materials and methods
All materials and methods used in this study are described in detail in papers I-
IV and only a brief summary is given below.
2.1 The antibody expression constructions
To produce the soluble 2-phenyloxazolone (Ox) binding Fab, scFv and Fv
fragments in E. coli (papers I, III) the corresponding expression units (Figure 8a)
were cloned into the pKKtac vector (Takkinen et al., 1991), which consists of
the tac promoter (ptac), the transcription terminator region (TT), lac repressor
(lacIq) from pMJR 1560 plasmid (Amersham) and the signal sequence coding
region of pectate lyase (PelB) of Erwinia carotovora (Lei et al., 1987). For
production of the membrane-anchored Ox scFv hexahistidyl tail fusion (Ox lpp-
scFv-H6) (paper II), the signal sequence of the major lipoprotein (lpp) of E. coli
and the nine N-terminal amino acids of the lpp were cloned into the pKKtac
expression vector as described earlier (Laukkanen et al., 1993).
For baculovirus surface expression (paper IV) the antibody fragments were
cloned under the polyhedrin promoter (ppolh) into the pFLAGgp64 vector,
which contained the signal sequence of the GLUR-D glutamate receptor, the
FLAG epitope and the gp64 gene (Kuusinen et al., 1995; Mottershead et al.,
1997)(Figure 8b).
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Figure 8. The expression units in (a) the pKKtac vector, (b) the pFLAGgp64
vector and (c) the phagemid vector used in this study contained DNAs encoding
for: SS, signal sequence; L, linker peptide; lpp, the major lipoprotein of E. coli;
H6, hexahistidinyl tail; FLAG, the epitope DYKDDDDK; AcNPVgp64, the
major envelope protein gp64 of the AcNPV; TM, transmembrane domain; myc,
the epitope EQKLISEEDLN and pIII protein (aa 1–406) of the filamentous
bacteriophage M13. ptac, tac promoter; ppolh, polyhedrin promoter; plac, lac
promoter; TT, transcription terminator; TAG, amber stop codon; f1+, phagemid
origin of replication.
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2.1.1 Construction of human scFv gene libraries
Construction of the human scFv/κ and scFv/λ gene libraries used in the paper IV
will be described in detail elsewhere (our unpublished results). Briefly, to
construct the scFv libraries the Ig genes were amplified and cloned from B
lymphocytes of healthy human donors. The VH chain repertoire was prepared by
amplifying the IgM specific cDNA and the L chain repertoire by amplifying
both Vκ and Vλ specific cDNAs (Marks et al., 1991). The PCR amplification of
the H and L gene repertoires was achieved using primer sets published
previously (Marks et al., 1991), and the gene repertoires were cloned into a
phagemid vector modified from the pBluescript SK vector (Stratagene). The
scFv/κ and scFv/λ libraries were estimated to contain 2.1 x 107 and 7.4 x 107
clones, respectively.
The phage display vector contained the lac promoter (plac), the pel B signal
sequence, the transcription terminator region (TT) and the phagemid origin of
replication (f1+) (Fig. 8c). The Ig V domains are joined by the (GGGGS)3 linker
peptide, the c-myc peptide tag permits detection of the scFv in immunoassays
and fusion to the pIII protein (aa 1–406) allows incorporation of the scFv into
the phage. The presence of the amber stop codon (TAG) between the myc tag
and the gene III allows (Fig. 8c) to switch between antibody fragment displayed
on the phage surface and soluble antibody fragment by use of either a suppressor
(XL-1 Blue) or a non-suppressor (HB2151) E. coli strain without recloning the
gene.
2.2 Expression and purification of the antibody
fragments
 The different pKKtac expression vectors (Fig. 8a) were transformed into the
expression host E. coli RV308. For induction the cells were grown to OD600 ∼
1.5, after which isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a
final concentration of 1 mM and the bacteria were grown overnight at 30 °C.
The secreted soluble antibodies were purified from the culture supernatants in
one step by affinity chromatography using an OxnBSA column (n = 19 or 22)
(papers I, III). Protein concentrations of the purified soluble antibody fragments
were determined from the A280 values using the molar extinction coefficients.
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The membrane-bound lpp-scFv-H6 antibody was first solubilized in detergent
from the isolated bacterial cell envelopes and then purified in two steps using
immobilized metal affinity chromatography (IMAC) and affinity
chromatography on Ox21BSA column as described in paper II.
2.3 Preparation of immunoliposomes
Immunoliposomes were prepared by adding the purified Ox lpp-scFv-H6 to a
mixture of pure egg yolk phospholipids (PC, PE) and cholesterol solubilized in
1% non-ionic detergent, n-octyl-β-D-glucopyranoside (OG). The detergent was
removed by dialysis in dialysis bags or in a LIPOSOMAT dialyzer (Dianorm,
Munich, Germany) and the immunoliposomes reconstituted were collected by
ultracentrifugation and suspended in 10 mM HEPES, pH 7.4 (paper II).
Liposomes prepared in the absence of the lipid-tagged single-chain antibody
were used as controls in the measurements.
2.4 Isolation of scFvs from a phage library
The scFv library DNAs containing the IgM VH sequences and either κ or λ VL
sequences cloned into the phagemid vector were transformed by electroporation
into E. coli XL-1 Blue cells (Stratagene, USA). The phage particles were
rescued by superinfection with the filamentous phage VCS-M13 (Stratagene,
USA) and a mixture of the scFv/κ and scFv/λ phage pools (1:2) was selected for
clones binding to human colon carcinoembryonic antigen (CEA) (Calbiochem)
using antigen-coated microtitre plate wells as described in paper IV. To decrease
non-specific binding the phage pool was preincubated in a blocked microtitre
plate well containing no antigen before incubation in a CEA-coated well. One
CEA-specific clone was isolated from the fifth round of panning. DNA encoding
the CEA-binding scFv was isolated, sequenced, cloned into the pKKtac vector
and transformed into RV308 cells for further characterization.
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2.5 Characterization of antibody binding properties
In this work ELISA was used to monitor the binding activities and specificities
of both the soluble and membrane-bound Ox- and CEA-binding antibodies as
described in papers I–IV. Fluorescence quenching (Eisen, 1964) was employed
to determine the affinity constants (KA) of the soluble anti-Ox antibody
fragments (papers I, III) as described previously (Takkinen et al., 1991). The
BIAcore biosensor was used to analyse the binding kinetics of the Ox IgG1 Fab
fragment (K. Alfthan, unpublished data), the different Ox scFv derivatives and
the Ox Fv fragment as described in paper III as well as the Ox-binding activity
of the immunoliposomes (paper II). BIAcore was also employed to test the
binding of the soluble CEA scFv isolated from the antibody phage library (K.
Alfthan, unpublished data). A periplasmic sample of an induced RV308/pKKtac
culture was run over CEA, which was immobilized on a CM5 sensor chip (190
RU) using the EDC/NHS amino coupling chemistry according to the
manufacturer´s instructions (BIAcore AB). Otherwise the conditions were those
described in paper III. An untreated sensor chip surface was used as a control
surface.
2.6 Other methods
Protein samples were analyzed by SDS-PAGE according to Laemmli (1970) and
then transferred onto a nitrocellulose filter (Towbin et al., 1979). For
immunostaining the filters were first incubated with specific antibodies
recognizing either the Ox antibody fragments (papers I–III) or other epitopes
fused to the proteins studied (paper IV), followed by incubation with an enzyme-
labelled antibody before addition of the substrate. Preparation of the OxnBSA
derivatives (n = 4–22) (papers I–IV) was performed basically as described by
Mäkelä et al. (1978).
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3. Results and discussion
Murine anti-2-phenyloxazolone antibody was chosen as a model antibody in this
work (papers I–IV), because it has been extensively studied and much
information was available on the maturation processes of the immune response
to 2-phenyloxazolone (Ox) (Kaartinen et al., 1983; Berek et al., 1985). In
addition, an anti-Ox antibody and its Ox-binding fragments have been used as
model molecules for structural and functional studies of antibodies (Alzari et al.,
1990; McManus and Riechmann, 1991). To extend the study to human
antibodies recognizing human proteins, CEA was used as a model antigen to
isolate single-chain antibody fragments from a phage library (paper IV).
3.1 Characterization of soluble antibody fragments (I and III)
3.1.1 Stability of Fab fragments (I)
The Ox Fab fragment used in our first studies was constructed from an Ox IgG3
class antibody. The production levels of the active Ox IgG3 Fab fragments in the
early experiments were consistently low, which prompted us to produce an Ox
Fab fragment of another subclass, Ox IgG1. In paper I we compared the
properties of these two different Fab fragments. The results showed that in the
case of Ox IgG1 the Fd and L chains were able to assemble to form the Fab
fragment while a minor amount of assembled Ox IgG3 Fab was detectable. The
L chains in both Ox IgG3 and Ox IgG1 Fab are identical as are also the VH
domains except for five amino acid residues located in the D-J region. Thus, the
main difference between the Ox IgG3 and Ox IgG1 Fab fragments is in the
amino acid sequence of the CH1 domain and in the interchain disulfide bond
arrangement (Fig. 9). On the basis of this information we tested the effect of the
CH1 domain on the assembly of the chains. We therefore truncated most of the
Fd chain while retaining the cysteine residue participating in the formation of the
interchain disulfide bridge (Fig. 9). Deletion of most of the Fd chain from the C-
terminus resulted in the assembly of a truncated, but fully functional Fab
fragment, Ox IgG3∆CH (paper I, Fig. 2).
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Figure 9. Schematic presentation of the interchain disulfide bond arrangement
in the Ox Fab fragments studied.
The correct processing of the PelB signal sequence of the L and Fd chains was
confirmed by N-terminal amino acid sequencing. In the case of the purified Ox
IgG3 Fab only correctly processed L chain was observed and no intact Fd was
detected. Several smaller molecular weight proteins were found, two of which
were identified as C-terminal degradation products of the Fd chain (paper I, Fig.
4A). In the native, folded state proteins are normally much more resistant to
cleavage by proteases compared to unfolded or misfolded molecules (Parsell and
Sauer, 1989). In the case of the IgG3 Fd chain the observed instability may
indicate problems in the folding of the Ox IgG3 Fab. A failure to produce
functional proteins in E. coli may result either from the absence or limiting
amount of appropriate molecular chaperones and/or disulfide isomerases
necessary for folding and formation of disulfide bonds (Baneyx, 1999). Recent
studies have led to the identification of new periplasmic catalysts, the
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coexpression of which was shown to improve the folding of antibody fragments
expressed in E. coli (Bothmann and Plückthun, 1998, 2000; Ramm and
Plückthun, 2000). On the other hand, the IgG3 subclass antibodies have a
tendency to aggregate and self-associate and at least in one case the site
responsible for aggregation was reported to be located in the Fd fragment (Capra
and Kunkel, 1970). Thus, precipitation in addition to the observed degradation
of the Fd chain during synthesis in E. coli cannot be ruled out.
Similar observations of the Fd chain on the production of functional Fab
fragments have been reported since the publication of paper I. It was shown
recently that replacing the CH1 domain of murine IgG2a and IgG2b antibodies
by that of the IgG1 subclass antibody significantly increased the production level
of immunoreactive Fab fragments (Pajunen et al., 1997). In addition, expression
of IgM Fab fragments in E. coli resulted in relatively low production levels and
accumulation of the L chains, probably due to precipitation of the Fd chain in the
periplasmic space of E. coli (Adib-Conquy et al., 1995; Jahn et al., 1995). The
CH1 domain of the IgM subclass antibody is glycosylated (Davies and Shulman,
1989), and thus the lack of glycosylation in bacteria may also contribute to the
low levels of IgM Fab in these cases. Interestingly, all these antibody types,
IgG2a, IgG2b and IgM, share the interchain disulfide bond arrangement with the
IgG3 antibody. At this point, it would be tempting to speculate that this kind of
interchain disulfide bond arrangement is involved in the non-productive folding
of Fab fragments in E. coli. However, the situation is more complex, as shown in
the case of human IgE Fab fragments (Steinberg et al., 1996), which have a
similar interchain disulfide bond arrangement to that of the IgG3 antibodies.
Nevertheless, the IgE Fab fragments have been successfully expressed on the
surface of bacteriophage, demonstrating the ability of the Fd chain to assemble
in E. coli (Steinberg et al., 1996). It also appears that the effect of the constant
domains on the production of functional Fab fragments is not limited to the Fd
chain, but that CL domains can also have a significant influence on the
expression of functional antibody fragments (MacKenzie et al., 1994). All these
results together emphasize that still more information is required to understand
all the factors influencing the productive folding and disulfide bond formation of
functional Fab fragments in E. coli.
The thermal stabilities measured for the different Fab fragments suggest that the
CH1 domain stabilizes the structure against denaturation. This is demonstrated
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by the results showing that the Ox antibody fragments lacking the CH1 domain
began to loose their activity already at 40°C, whereas those antibodies having an
intact CH1 domain were active up to 60°C (paper I, Fig. 5). In another study it
was observed that glycerol decreases the binding affinity of the scFv fragment,
although no effect of the glycerol on the activity was observed for the Fab
fragment or the whole monoclonal antibody (Müller et al., 1994). It was
suggested that the constant domains adjacent to the V domains provide
additional stabilization of the molecular structure at the antigen binding site. By
using phage display technology, it is now possible to generate antibody
fragments and other proteins with improved stability by performing the selection
steps at elevated temperatures or in the presence of denaturants or proteases
(Chowdhury et al., 1998; Sieber et al., 1998; Jung et al., 1999).
3.1.2 Stability of scFv and Fv fragments (III)
In an earlier work we constructed an Ox scFv in which the C-terminus of the VH
domain was joined to the N-terminus of the VL domain by a 28 amino acid
residues long interdomain peptide of the Trichoderma reesei cellobiohydrolase I,
CBHI (Fig. 10) (Takkinen et al., 1991). Initially, the CBHI linker peptide was
chosen because it represents a flexible linker in a naturally secreted multidomain
protein. The Ox scFv was secreted into the periplasm of E. coli and released as
an active hapten binding fragment into the culture medium. During the bacterial
production we observed occasional proteolytic degradation of the linker peptide,
the extent of which varied between cultivations. Even when degradation
occurred it was not so extensive as to prevent the use of these scFvs fragments in
our studies. The yields of the intact fragment were satisfactory and allowed
functional characterization of the antibody.
The proteolytic cleavage sites (↓) of the CBHI linker were determined by N-
terminal amino acid sequencing and three sites were identified: R5↓G6,
R11↓R12 and H27↓Y28 (Fig. 10). In order to improve the stability of the CBHI
linker, we constructed shorter linker variants of 11, 6 and 2 amino acid residues
by omitting the identified proteolytic cleavage sites (Fig. 10). This truncation of
the linker was prompted by the molecular model constructed earlier for the Ox
Fv fragment (Holm et al., 1990; Hoffrén et al., 1992), which suggested that both
the C-terminus of the VH domain and the N-terminus of the VL domain are
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flexible enough to serve as part of the linker. In addition to these CBHI linkers,
we tested the performance of two other linkers, a 15 amino acid residues long
(GGGGS)3 linker (Huston et al., 1988) and a 22 amino acid residues long IgG2b
hinge sequence (Bell et al., 1990) (Fig. 10), in which the four Cys residues of the
original sequence were replaced by Ser residues. In addition to the different Ox
scFv derivatives, a corresponding Ox Fv fragment without any joining peptide
between the V domains was produced.
Figure 10. Linker peptide sequences used in this study. The proteolytic cleavage
sites are indicated by arrows.
Attempts to improve the stability of the scFv molecule by truncation of the
CBHI linker peptide revealed that the degradation could not be completely
avoided simply by omitting the identified protease sensitive sites in the linker
peptide. In addition it was also observed that the Ox scFv with the modified IgG
2b linker was cleaved into two smaller fragments after purification, probably due
to the presence of copurified proteases (paper III, Fig. 3A). N-terminal amino
acid sequencing revealed that the proteolytic cleavage site was located in the
linker peptide at the site T8↓I9 (Fig. 10). One approach to minimize or avoid
proteolytic degradation might be to produce the antibody fragments as insoluble
proteins into the bacterial cytoplasm, as inclusion bodies are often protected
from degradation (Baneyx, 1999). This strategy, however, requires effective in
vitro refolding steps, which may be laborious and time-consuming to optimize.
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In this study the observed proteolytic degradation of the Ox scFv fragment could
not be eliminated by replacing the CBHI linker by the (GGGGS)3 linker. Some
amounts of low molecular weight proteolytic degradation products were
observed in both cases (paper III, Fig. 2). However, the functionality of the
(GGGGS)3 linker has been demonstrated in several studies and currently the
most frequently used linkers are composed of repeats of glycine and serine
residues. The flexibility of the (GGGGS)3 linker has been confirmed by NMR
and it was also observed that the linker peptide had essentially no influence on
the structure of the V domains (Freund et al., 1993). As well as the (GGGGS)3
linker (Huston et al., 1988) longer derivatives even up to 30 amino acid residues,
(GGGGS)6, have been used (Nieba et al., 1997). The results of several recent
studies suggest that phage display combined with random mutagenesis of the
linker might provide a rational means to optimize the linker sequence (Tang et
al., 1996; Turner et al.,1997; Hennecke et al., 1998).
Since publication of our study on Ox scFv (Takkinen et al., 1991), the CBHI
linker peptide has been applied to construct also other scFv molecules. For
example, a modified CBHI´ linker containing 24 amino acid residues was
employed to join two scFvs with different binding specificities in order to
construct a bispecific scFv produced in E. coli (Mallender and Voss, 1994). In
this study the antibody fragments accumulated in bacteria as insoluble inclusion
bodies and although smaller antibody fragments were detected in the sample
after purification, no instability of the CBHI´ linker was reported. The CHBI
linker has also been used to join the V domains of a CEA specific antibody and
the performance of this scFv for tumor localization in vivo was compared to that
of an scFv with the 14 amino acid residues long "212" linker (Bedzyk et al.,
1990). It was noticed that the scFv containing the linker "212" had better
pharmacokinetic properties than the scFv with the CBHI linker. Proteolytic
cleavage of the CBHI linker in vivo was suggested as one of the possible
explanations for this difference between the two scFvs (Wu et al., 1996).
During this work we did not observe any proteolytic degradation of the Ox Fv
fragment. However, the V domains of the Fv fragments are known to dissociate
at low protein concentrations (Glockshuber et al., 1990). Although the Fv
fragments are less stable than the scFv fragments, the apparent stability of the Fv
molecules is increased with high protein concentration and in the presence of the
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antigen (Jäger and Plückthun, 1999). In our study we observed instability of the
Ox Fv fragment during the hapten binding studies (see 3.1.3).
3.1.3 Binding properties of the antibody fragments (I and III)
The Ox scFv constructed earlier showed hapten binding affinity comparable to
that of the corresponding parental monoclonal antibody indicating that the CBHI
linker peptide used to join the V domains did not disturb Ox binding of the scFv
molecule (Takkinen et al., 1991). In this work we determined the hapten binding
properties of several other recombinant antibody fragments produced in E. coli
using ELISA, BIAcore and fluorescence quenching.
In order to study the effect of the linker peptides on the hapten binding activity
of the Ox scFv molecule, the different scFv derivatives (see Fig. 10) were first
measured by ELISA. The results suggested similar hapten binding activities of
the original Ox scFv and the Ox scFv with the (GGGGS)3 linker, whereas
increased activity was observed for the shorter Ox scFv derivatives (paper III,
Fig.4). Further, the binding activity appeared to be inversely proportional to the
length of the linker; the shortest derivative showed the highest response,
approaching that of the intact antibody. Earlier observations had suggested that
the use of short linker peptides drives dimerization of the scFvs (Holliger et al.,
1993). Gel filtration analysis of the Ox scFv derivatives revealed that the
original Ox scFv and the one with a (GGGGS)3 linker were monomeric, whereas
the shorter derivatives existed in several different forms. Results obtained later
by others supported our observation that the use of the CBHI linker allows
folding of the V domains, resulting in a monomeric scFv (Wu et al., 1996),
while with the (GGGGS)3 linker both monomeric (Iliades et al., 1997) and
multimeric (Desplancq et al., 1994) forms were observed. The multimerization
appears to be concentration-dependent, increasing antibody concentrations
driving the formation of multimers (Desplancq et al., 1994). In addition to
dimers, trimers, tetramers or even higher molecular mass multimers have been
obtained either by using short linkers or by omitting the linker peptide (Iliades et
al., 1997; Kortt et al., 1997; Atwell et al., 1999; Le Gall et al., 1999; Dolezal et
al., 2000). Competitive ELISA was used to confirm the binding specificity of all
the antibody fragments (data not shown). However, in the case of the Ox Fv
fragment problems were encountered in attempts to obtain a linear correlation
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between sample dilution and absorbance, probably due to dissociation of the V
domains during the experiment (Glockshuber et al., 1990; Jäger and Plückthun,
1999).
The BIAcore biosensor was used to analyze the binding kinetics of the different
Ox scFv derivatives and the corresponding Ox Fv fragment. Attempts to
separate the different molecular forms of the truncated Ox scFv fragments by gel
filtration did not give satisfactory resolution and samples containing mixtures of
the different molecular forms were taken for BIAcore analysis. Two different
epitope densities, high (Ox16BSA) and low (Ox4BSA), were chosen in order to
see the possible effects caused by the differences in the binding valencies of the
samples. The binding data was evaluated using the 1:1 interaction model
available in the kinetic software supplied by the manufacturer at that time.
Although the interaction of multivalent antibodies with the antigen is much more
complex this simple set-up allowed us to compare the relative binding properties
between the different samples.
The analysis revealed that the Ox scFvs with the truncated CHBI linkers showed
higher apparent KA values than the original Ox scFv and the Ox scFv with the
(GGGGS)3 linker, which is consistent with the results obtained by ELISA. The
KA value of the Ox Fv determined on the high epitope surface was close to that
of the parental monoclonal antibody (1.5 x 10-6M-1, Takkinen et al., 1991)
determined by the fluorescence quenching method, whereas higher KA values
were obtained with all the other samples. The KA values on the low epitope
surface were lower than those obtained on the high epitope surface (paper III,
Table I) and in the case of the original Ox scFv and the Ox scFv with the
(GGGGS)3 they were close to those values obtained by the fluorescence quench
titration (Table I). The responses of the Ox Fv on the low epitope surface were
too low to rely on. The Ox scFv derivatives with the truncated CBHI linkers
dissociated more slowly from the high epitope surface than from the low epitope
surface due to the presence of bi- or multivalent fragments, whereas the
monovalent Ox scFv fragments dissociated with similar rates from both surfaces.
Slow dissociation of bivalent or multivalent antibody fragments has also been
reported by other workers (reviewed in paper V). The kinetic constants
determined with both low and high epitope densities for the Ox IgG1 Fab (K.
Alfthan, unpublished data) were close to those obtained for the monomeric Ox
scFv fragments. The KA values determined on the low epitope surface for all the
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monovalent fragments were close to those obtained with the fluorescence
quenching method and were also comparable to that of the parental monoclonal
anti-Ox antibody (Table 1).
Table 1. Kinetic constants, kass,, kdiss and KA (kass/kdiss) determined for the
monomeric Ox antibody fragments by BIAcore on the Ox4BSA surface (paper III,
unpublished results) and the KA values determined by fluorescence quenching
(FQ) (papers I, III).
kass kdiss KA KA(FQ) 
(M-1s-1) (s-1) (M-1) (M-1)
Ox scFvCBHI 3.6 x 103 2.5 x 10-3 1.4 x 106 0.9 x 106
Ox scFv(GGGGS)3 7.4 x 103 1.5 x 10-3 4.9 x 106 1.1 x 106
Ox IgG1Fab 7.4 x 103 2.7 x 10-3 2.7 x 106 1.8 x 106
KA value of parental Ox IgG1: 1.5 x106 M-1 (Takkinen et al., 1991)
The affinities of the Ox IgG3∆CH and of the Ox IgG3 Fab fragments were
determined by the fluorescence quench titration and found to be close to those of
the parental monoclonal antibody. The observed binding activity of the Ox IgG3
Fab fragment is probably a result of noncovalent pairing of the L chain with the
C-terminal degradation products of Fd chains, which are still able to form an
intact and relatively stable antigen binding cavity. By contrast, attempts to
determine the KA values of the Ox Fv by fluorescence quenching gave different
KA values for different Fv concentrations, indicating instability of Fv fragments,
which has been found to be concentration dependent (Glockshuber et al., 1990;
Jäger and Plückthun, 1999).
63
3.2 Characterization of scFvs displayed on liposomes (II)
It was earlier shown that fusion of the signal peptide and the nine N-terminal
amino acid residues of the major lipoprotein of E. coli (lpp) to the Ox scFv with
the 28 amino acid CBHI linker led to expression of an active lipid-modified
single-chain antibody, which behaved like a membrane protein (Laukkanen et
al., 1993). The work in paper II describes the functional reconstitution of this
biosynthetically lipid- and histidine-tagged Ox lpp-scFv-H6 in liposomes. The
Ox lpp-scFv-H6 was expressed in E. coli and purified in two steps by applying
IMAC followed by a hapten affinity chromatography. The purified, detergent
solubilized Ox lpp-scFv-H6 was reconstituted in active form into liposomes by
dialysis. The average number of antibody molecules per liposome was calculated
to be about 2000. In addition the detergent dialysis method was thought to lead
to a 50/50 distribution in terms of inward/outward orientation of the
reconstituted protein.
In therapeutic and diagnostic approaches both the strength and specificity of the
antibody-antigen interaction mediating the binding of liposomes to the antigen is
of crucial importance. The multivalent binding obtained by display of many
antibody molecules on the surface of liposomes can be thought to lead to higher
binding avidity. In this study the Ox binding of the immunoliposomes was
analyzed in BIAcore by running the liposomes on a sensor chip surface with
immobilized Ox16BSA. The results showed increased binding of the
immunoliposomes to Ox16BSA compared to BSA used as a control surface
(paper II, Fig. 5B). Also liposomes lacking the antibody did not bind to either
surface. The binding of the Ox scFv displayed on liposomes was inhibited in the
presence of the soluble hapten in a concentration dependent manner which
confirmed the specificity of the binding (paper II, Fig.6). We also tested the
hapten binding activity of the soluble lipid-tagged Ox scFv in BIAcore in the
presence of different detergents (Triton X-100, n-octyl β-D-glucopyranoside). In
contrast to the soluble Ox scFv, no reproducible binding of the lipid-tagged Ox
scFv was observed. As demonstrated by both the successful affinity purification
of the fragment and ELISA assay, the presence of the detergent as such allows
the lipid-tagged Ox scFv to bind the hapten (paper II, Fig. 3). The reason for this
discrepancy is not clear.
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Dissociation of the immunoliposomes from the hapten surface analyzed in
BIAcore was extremely slow compared to that of the soluble Ox scFv (paper II,
Fig.5C), which is in good agreement with the expected multivalent binding of
immunoliposomes. The determination of the affinity constant for the interaction
between the hapten and the scFv fragments displayed on the liposomes was not
possible in the assay format used in this study. This was because the
concentration of the active antibody molecule has to be known, but this was not
possible in our experimental design. At this point further studies on binding
kinetics were not performed. However, it is possible to analyze interaction
kinetics of molecules displayed on liposomes by capturing the intact liposomes
on a sensor surface (Masson et al., 1994; MacKenzie et al., 1997; Harrison et
al., 1998). For the kinetic analysis, the other binding partner can then be
supplied in different concentrations over this liposome surface. New modified
sensor chips designed either to immobilize intact liposomes or to form a lipid
layer generated from the liposomes on the sensor surface may provide another
useful approach in future studies (Cooper et al., 1998; Erb et al., 2000). This
development in surface chemistry allows analysis of biomolecular interactions in
a membrane environment, and thus may open new possibilities in membrane
protein research.
The potentiality of the immunoliposomes as specific, stable and signal-
amplifying immunodiagnostic reagents was demonstrated in later studies, in
which either europium-chelate (Laukkanen et al., 1995) or carboxyfluorescein
(Kobatake et al., 1997) was encapsulated as a fluorescent marker in
immunoliposomes harboring the lipid-tagged Ox.
3.3 Characterization of scFvs displayed on baculovirus (IV)
Recombinant baculoviruses can be used for efficient production of proteins with
post-translational modifications such as glycosylation, phosphorylation, acylation
and palmitylation and therefore serve as potential candidates for a eukaryotic
display system. Baculoviruses are not inherently pathogenic for mammalian
cells and thus possess potential for use as gene delivery vehicles (Hofmann et
al., 1995). To target the virus it is possible to introduce cell specific molecules
on the viral surface. One approach for the specific targeting is presented in paper
IV, in which the ability of baculovirus to display functional scFv fragments and
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synthetic IgG-binding domains (Z and ZZ) was studied. Three different scFvs
were chosen for this work, two of which were murine Ox scFvs, one with the 28
amino acid CBHI linker and the other with the (GGGGS)3 linker (Fig. 10). The
third scFv containing the (GGGGS)3 linker peptide was specific for CEA and
was isolated from a naive human scFv library (see below). CEA is expressed on
different cancer cells, e.g. colorectal carcinoma cells and it has been used as a
marker in determining and monitoring the status of malignant diseases (Konishi
et al., 1998).
3.3.1 Isolation of scFvs from a phage library
To isolate CEA-specific scFvs (CEA scFv), a mixture of the human scFv/κ and
scFv/λ phage libraries (~ 1011 phage particles) was incubated on a CEA-coated
microtitre plate well after preincubation on a blocked well without the antigen.
After five rounds of selection the DNA pool was isolated and transformed to a
non-suppressor E. coli strain (HB2151) to produce soluble scFvs. The
expression of the scFv was confirmed from both the culture supernatant and the
periplasmic fraction by immunoblotting, and the CEA specific clones were
identified from the culture supernatants by ELISA. Three CEA-binding clones
were identified from the twenty clones analyzed. These three positive clones
were sequenced and found to have identical DNA sequences. The deduced
amino acid sequences of the CDRs found in this clone were similar to those of
the CEA scFvs isolated earlier by other groups from naive human scFv libraries
(data not shown).
The antigen binding activity of the CEA scFv was tested in BIAcore by running
the periplasmic fraction isolated from the induced RV308 culture on the sensor
chip surface with immobilized CEA. A low but significant binding response was
observed, compared to a control (untreated) sensor chip surface (K. Alfthan,
unpublished data) (Fig. 11). The specificity of the isolated CEA scFv was
confirmed by competition ELISA from the culture supernatant (paper IV, Fig. 2).
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Figure 11. Binding of the isolated scFv on immobilized CEA analyzed by
BIAcore. The background signal obtained on the control surface has been
subtracted.
3.3.2 Binding properties of the scFvs displayed on baculovirus
For the expression on the surface of virions, the two Ox scFvs and the CEA scFv
were fused to the N-terminus of the major envelope protein, gp64, of the
baculovirus AcNPV. All the antibodies were incorporated into the virion,
although the amount of the Ox scFv with the CHBI linker was significantly
lower than that of the two other scFvs with the (GGGGS)3 linker peptide (paper
IV, Fig. 4). These two Ox scFv fragments differ from each other only with
respect to the linker, and the Ox scFv with the 28 amino acid CBHI linker is
known to be produced as a soluble and active antibody in E. coli (Takkinen et
al., 1991; paper III). The CBHI linker is rich in Ser and Thr residues, which in
the filamentous fungus Trichoderma reesei are known to be O-glycosylated
(Tomme et al., 1988; Salovuori et al., 1987). It is possible that the high degree
of the O-glycosylation in the linker peptide during expression in insect cells
interferes with the incorporation of this scFv into the baculovirus particle.
The antigen/hapten binding ability of the scFvgp64 fusions was first
demonstrated by ELISA from the cell lysates from virus-infected insect cells
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(paper IV, Fig. 5). The expression of the scFv fragments on viral particles and
the specificity of the binding were then confirmed from the viral supernatants
using competitive ELISA (paper IV, Fig. 6). The only scFv fusion protein,
which failed to give ELISA signals above the background, was the Ox scFvgp64
with the CBHI linker. This is consistent with the low incorporation of this fusion
protein into the virus particle (paper IV, Fig. 4). Throughout the ELISA
experiments the CEA scFvgp64 fusion showed the highest signal of all the scFv
fusion proteins tested. The CEA scFv was originally isolated from a phage
display library, demonstrating that this scFv is well expressed in bacteria. The
results obtained in this study suggest good expression of this fragment also in the
eukaryotic display system applied. It has been shown earlier that selection of the
scFv phage libraries on microtitre plate wells favours enrichment of scFv
fragments forming dimers (Schier et al., 1996a). Neither the presence of dimers
nor the binding affinity of the CEA scFv was studied in this case. As another
approach to confirm the specific hapten/antigen binding of the scFvgp64 fusions,
the virus particles were analyzed in BIAcore by running the infected cell culture
supernatants on immobilized Ox16BSA or CEA. However, interpretation of the
results was hampered by non-specific binding of the virus on the sensor chip
surface. The gp64 fusion proteins are transported onto the surface of infected
insect cells, from which they are then incorporated into the budded virus
particles. Thus, one possibility to control production of functional pg64 fusions
is to analyze by FACS the binding of the proteins expressed on the infected
insect cells rather than the virus particles themselves (Ernst et al., 1998).
The baculovirus display system may prove to be a useful display technology for
large, complex eukaryotic proteins that cannot be processed post-translationally
correctly in bacteria. Currently, however, the construction of large baculovirus
display libraries is limited by the relatively low transfection efficiency (6.6 x 105
clones/µg viral DNA, Ernst et al., 1994). Further, the amount of recombinant
fusion protein present on the viral envelope compared to the native gp64 protein
is relatively low, necessitating means to increase the display efficiency. Due to
the fragile nature of the AcNPV budded viruses (Summers and Volkman, 1976;
Mottershead et al., 1997), the selection and screening methods used to isolate
binders from the phage display libraries are most probably not applicable to
baculovirus display system and thus the development of new, gentle but efficient
selection and screening methods is needed. Despite these apparent limitations, a
proof of the principle of the display of active antibodies on the surface of
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baculovirus was demonstrated in this work, and future development of the
methodology will eventually show the usefulness of the baculovirus system both
in the display technology and in gene therapy.
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4. Conclusions
Antibodies have been targets of intensive protein engineering due to their
practical importance in medical, diagnostic and research applications. As shown
in this work and by others, a number of different antibody fragments can be
expressed in E. coli as active antigen-binding proteins. By utilizing the bacterial
secretory machinery the proteins are produced in their native state and no in
vitro refolding is needed. However, the expression levels of the functional
antibodies may vary widely. This work demonstrated that the stability of the
antibody fragments against proteolysis during their production in bacteria is one
of the factors, which influences the yield of the functional fragments. The
susceptibility to proteases may arise from incomplete folding of the antibody
fragments or the presence of proteolytic cleavage sites in the engineered
antibodies. Two findings of specific importance were made. Firstly, it was
observed that the production of stable and active mouse Fab fragments depends
on the first constant domain of the heavy chain. Comparison of the IgG3 and
IgG1 Fab indicated the superiority of the latter for the production of active
properly assembled Fab fragments in E. coli. Secondly, the results indicated that
a linker peptide is necessary to stabilize the Fv fragment, but that the linker
region may be susceptible to proteolytic degradation. In addition it was
demonstrated that linker peptides shorter that 12 amino acids promote the
formation of dimeric or multimeric scFvs, which showed increased binding
activities compared to the monomeric scFvs.
The development of antibody phage display technology for generating
antibodies with improved or novel binding properties has opened new
possibilities in the entire field of antibody technology. In this work, two
alternative antibody display systems, liposome display and baculovirus display,
were explored. Liposomes displaying antibody fragments have potential
applications in immunoassays, targeted drug delivery and gene therapy. This
work demonstrated that a biosynthetically lipid-tagged scFv can be immobilized
in a stable and orientated manner onto liposomal membranes, which allows
reconstitution of active hapten-binding immunoliposomes. Biosynthetic lipid-
tagging of bacterially expressed antibody fragment provides an alternative for
chemical conjugation of antibodies to liposomes. Expression of foreign proteins
on the baculovirus surface provides a means for functional display of complex
eukaryotic proteins. In this work the baculovirus display system was studied
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using single-chain antibodies as model proteins. Baculoviruses carrying a cell-
targeting function, such as antibodies, have aroused interest as a gene transfer
vehicle. It was shown that fusion of the scFv fragments to the baculovirus major
envelope protein led to the expression of active scFv fragments on the surface of
the virus particles.
This work and many others show that antibodies are molecules which are
compatible with a number of expression systems and that they tolerate
significant structural modifications without loss of the binding function. The
enormous application potential, limited only by the imagination, will thus
continue to make antibody engineering increasingly popular in many areas of
research as well as in medical and industrial applications.
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